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Little is known about how a neuron undergoes site-specific changes in intrinsic 
excitability in normal and diseased conditions. We provide evidence for a novel 
mechanism for the mammalian Target of Rapamycin Complex 1 (mTORC1) 
kinase dependent translational regulation of the voltage-gated potassium channel 
Kv1.1 mRNA (Chapter 2). First, we identified a microRNA, miR-129-5p, that 
represses Kv1.1 mRNA translation when mTORC1 is active. When mTORC1 is 
inactive, we found that the RNA-binding protein, HuD, binds to Kv1.1 mRNA and 
promotes its translation. Surprisingly, mTORC1 activity does not alter levels of 
miR-129 and HuD to favor binding to Kv1.1 mRNA but affects the degradation of 
high-affinity HuD target mRNAs, freeing HuD to bind Kv1.1 mRNA. Thus, high 
affinity HuD target mRNAs can serve two purposes under normal physiological 
conditions: 1) to provide functional proteins, such as CaMKIIα, that change the 
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architecture of the synapse and 2) serve as a sponge sequestering HuD from 
translating mRNAs like Kv1.1.  
To determine if this mechanism for repression of Kv1.1 expression is 
conserved in a disease model where mTORC1 activity is overactive, we 
assessed the expression levels of active mTORC1, Kv1.1, and miR-129-5p in a 
rat model of temporal lobe epilepsy (TLE; Chapter 3). We found that when mTOR 
activity is low in TLE, Kv1.1 expression is high and behavioral seizure number is 
low. In contrast, when behavioral seizure activity starts to rise there is a 
corresponding increase in mTOR activity and Kv1.1 protein levels dramatically 
drop. In addition, we found that miR-129-5p, the negative regulator of Kv1.1 
mRNA translation increases by 21 days post status epilepticus (SE) to sustain 
Kv1.1 mRNA translational repression. Thus, long-term changes in Kv1.1 protein 
levels result in a hyperpolarized threshold for action potential firing. Our results 
suggest that increased mTOR activity following SE results in two phases of Kv1.1 
repression (1) in an initial repression of Kv1.1 mRNA translation by mTOR 
activity that is followed by (2) an onset of elevated miR-129-5p expression that 
sustains Kv1.1 repression. These studies suggest that dynamic changes in miR-
129-5p provide potential novel targets for epilepsy interventions. 
mTOR is a protein kinase that promotes CaMKIIα mRNA translation 
(Sosanya et al., 2013; Chapter 2); however, the mechanism and site of dendritic 
expression are unknown. Herein (Chapter 4), we show that mTOR activity 
mediates the dendritic branch specific expression of CaMKIIα, favoring one 
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secondary, daughter branch over the other in a single neuron. Notably, reduction 
in mTOR activity decreases the overall dendritic expression of CaMKIIα protein 
and RNA through the shortening of its poly(A) tail. Overexpression of HuD both 
increases total CaMKIIα levels and rescues the selective expression of CaMKIIα 
in one daughter branch over the other. These results suggest that differential 
branch targeting of HuD may mediate the branch specific expression of CaMKIIα 
in neuronal dendrites during mTOR activity. Furthermore, when mTOR activity is 
reduced HuD releases CaMKIIα mRNA and thus exposes its poly(A) tail to be 
deadenylated, reducing its overall expression and eliminating its branch specific 
expression. 
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Chapter 1: Dynamic Local Translation Promotes/Impairs 
Homeostatic Plasticity in Learning and Disease 
 
Introduction 
 
 Local dendritic translation, in recent years, has emerged as a key regulator of 
neuronal development and plasticity (Di Liegro et al., 2014). Precise temporal and 
spatial regulation of local translation is required for normal brain function. When this 
precision is interrupted it can have a devastating impact leading to learning disorders or 
disease. Several pathways and regulators are important to maintain the precision 
associated with local translation. Here, we will discuss some pathways involved in 
regulating local translation and when dysregulated the potential consequences. We will 
also discuss how future treatment options that regulate local translation may exist. 
 
Homeostatic Plasticity 
 Homeostatic plasticity is defined here as an adaptive, compensatory 
mechanism to maintain neuronal excitability within an optimal range. It is important to 
note that several forms of homeostatic plasticity mechanisms have been reported (Lee 
et al., 2013). Here, we focus on how local translation can either compensate for or 
contribute to learning difficulties or disease states.  
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ERK and mTOR Signaling Pathways:  
Local Translational Regulation 
 Both the extracellular signal-regulated kinase (ERK) and mammalian target of 
rapamycin (mTOR) pathways are known to promote local translation (Wang et al., 
2010). mTOR is a serine/threonine kinase that promotes cap-dependent translation by 
phosphorylating p70 S6 kinase (S6K) and elF4E binding protein (4E-BP). In neurons, 
mTOR kinase is activated by the Ca2+-dependent activation of PI3Kinase and has been 
found to be active in dendrites (Hoeffer and Klann, 2009; Tang et al., 2002). ERK is 
known to promote local translation by phosphorylating p90 ribosomal S6 kinase (RSK) 
and Ca2+-dependent ERK activation can underlie both LTP and LTD (Gallagher et al., 
2004; Kelleher et al., 2004; Merlin et al., 1998; Pende et al., 2004; Thiels et al., 2002). 
Thus, mTOR- and ERK-dependent, local protein synthesis has the unique advantage 
over somatic translation and protein trafficking by making available a rapid and spatially 
specific source of new proteins that can function to maintain homeostatic plasticity or 
when dysregulated can facilitate an imbalanced network. 
 One example of mTOR-dependent local translation mediating homeostatic 
plasticity is the reversal of cocaine-evoked synaptic plasticity which, with acute cocaine 
exposure, is initially characterized by a reduction in excitation. This is due to GluA2-
containing AMPARs being exchanged for GluA2-lacking receptors and decreased 
NMDAR function. Over time mTOR-mediated local translation of GluA2-containing 
AMPARs allows for the synapse to reset back to its original channel composition and 
function (Mameli et al., 2007). Thus, local translation may function as a neuroprotectant 
against drug abuse by regulating homeostatic plasticity. It will be interesting to 
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determine if local translation may act to reset channel composition with acute exposure 
to other drugs of abuse. For example, mTOR activity has been shown to be protective 
against craniofacial defects observed in fetal alcohol spectrum disorders (FASD) 
(McCarthy et al., 2013). 
 
Epilepsy 
 One example of how local translation may push the neuron into a 
hyperexcitable state is in the development of chronic epilepsy. Temporal Lobe Epilepsy 
(TLE) is characterized by an increase in hyperexcitability within the neocortex and 
hippocampal neuronal network and this is associated with a variety of molecular 
changes. Traumatic brain insult such as stroke or infection can result in the 
development of TLE and the kainate animal model of acquired epilepsy recapitulates 
the neuropathological damage observed in the human brain (Buckmaster et al., 1997; 
Hellier et al., 1998; Dudek et al., 2006).  
 It is well documented that the mTOR and ERK pathways are deregulated in 
epilepsy and mTOR specific blockade can reverse seizure activity suggesting that 
mTOR inhibition could have anti-epileptogenic action (Wong and Crino, 2012; Zeng et 
al., 2009). Autism Spectrum Disorders, such as Tuberous Sclerosis complex (TSC) and 
Fragile X Syndrome (FXS), where both the mTOR and ERK pathways are dysregulated, 
have a greater susceptibility to developing epilepsy (Potter et al., 2013; Stafstrom et al., 
2012). This may be, in part, due to the local translation of plasticity related genes, such 
as Arc. Local translation of Arc in FXS has been shown to result in the internalization of 
AMPA receptors contributing to epileptic firing (Bianchi et al., 2009; Bramham et al., 
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2008; Nakamoto et al., 2007; Stafstom et al., 2012). It will be interesting to further 
determine how regulation of RNA binding factors contribute to the local translation of 
receptors and channels involved in seizure development.  
 
Voltage Gated Potassium Channel: Kv1.1 
 The six transmembrane voltage gated potassium channel, Kv1.1, is transcribed 
from the KCNA1 gene. Kv1.1 is evolutionarily conserved from the Shaker potassium 
channel in Drosophila to its mammalian orthologue (Papazian et al., 1987; Tempel et 
al., 1987; Tempel et al., 1988). Kv1.1 can control the frequency and duration of the 
action potential (Smart et al., 1998; Foust et al., 2011; Bucher and Goaillard, 2011; 
Debanne et al., 2011). There are several Kv1.1 channelopathies, including a null 
mutation which can result in epilepsy (Smart et al., 1998). Mutations in Kv1.1 can also 
result in type 1 episodic ataxia which is characterized by ataxia (disrupted muscle 
coordination) with or without myokymia (Browne et al., 1994).  
 RNA editing of Kv1.1 has been recently investigated in patients with temporal 
lobe epilepsy (TLE). RNA editing of Kv1.1 leads to an amino acid exchange of 
isoleucine for valine in the S6 segment of Kv1.1 mRNA (Hoopengardner et al., 2003). It 
was found that there is a negative correlation between RNA editing of Kv1.1 and the 
length of time from seizure onset (Krestel et al., 2013). In vitro studies have shown that 
increased Kv1.1 RNA editing results in less affinity of Kv1.1 to bind an inactivation 
subunit resulting in more outward K+ current with membrane depolarization (Bhalla et 
al., 2004). Therefore, decreased I/V editing may conceivably result in disrupted 
repolarization and contribute to observed hyperexcitability in TLE (Krestel et al., 2013). 
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Further elucidation of the effect of RNA editing on Kv1.1 function and possible 
contribution to TLE is also needed. 
 Kv1 channels are present in both axons and neuronal dendrites (Storm, 1988; 
Metz et al., 2007). Kv1.1 mRNA also localizes to neuronal dendrites where it undergoes 
local translation under the control of the PI3K/mTOR pathway (Raab-Graham et al., 
2006). We have recently found that the mTOR mediated negative regulation of Kv1.1 
local translation is dependent on the microRNA, miR-129, and Kv1.1 expression in 
dendrites is promoted by the RNA binding protein, HuD (Sosanya et al., 2013, Chapter 
2). Kv1.1 KO mice also either die early or develop spontaneous seizures (Rho et al., 
1999) and it has been shown that Kv1.1 overexpression following seizure onset can 
reverse established seizure activity (Wykes et al., 2012). Collectively, these findings 
have led us to consider the relationship of miR-129 and HuD to Kv1.1 expression and 
function in TLE (Chapter 3). 
 
RNA Binding Factors: microRNAs and miR-129 
 microRNAs (miRNAs) bind to and result in reversible translational suppression 
and/or degradation of their mRNA targets (Djuranovic et al., 2012). miRNAs are first 
transcribed, either from an intron or regulated by its own specific promoter, to its pri-
miRNA form.  This primary miRNA transcript is cleaved to its pre-miRNA (~70 nt) form 
by the Drosha complex. Following nuclear export, the Dicer complex cleaves this 
transcript to the active mature miRNA (21-23 nt). Regulation of miRNA expression can 
occur at any of these stages of miRNA biogenesis. The mature miRNA is then loaded 
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onto the Ago-RISC complex where it will be targeted to specific mRNA binding 
sequences. 
 mTOR activity itself can be regulated by RNA binding factors, including small 
noncoding microRNAs. Recently, several factors of the PI3K/AKT signaling pathway, 
including mTOR and S6K2, have been shown to be direct targets of the miRNA, miR-
193a-3p/5p, where their mRNA levels are significantly depressed by miR-193a (Yu et 
al., 2014). 
 Contextual conditioning and NMDA neuronal stimulation results in changes in 
certain miRNA levels in the hippocampal CA1, including miR-129, (Jeong Kye et al., 
2011) suggesting a possible key role for miR-129 in learning and memory. Several of 
these miRNAs are possible regulators of the mTOR pathway and in particular miR-19b 
suppression increased PTEN levels resulting in decreased mTOR activity (Jeong Kye et 
al., 2011). 
 Currently, miR-129 has been extensively studied in several types of cancer 
cells suggesting that aberrant expression of miR-129 may be important in several 
different disease types (Dyrskjøt et al., 2009). It has previously been shown that in both 
colorectal and gastric cancer, methylation of the miR-129-2 promoter results in the 
decreased expression of miR-129-5p (Bandres et al., 2009; Shen et al., 2010).  Little is 
known about miR-129 role in the brain including its function in TLE.  
 
RNA Binding Proteins: HuD 
 RNA binding proteins (RBPs) are trans-acting factors that are essential to the 
correct spatiotemporal expression of numerous proteins that function in multiple 
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processes, including learning and memory. Cis-acting elements or structures direct 
specific RBPs to bind certain mRNA targets (Bronicki and Jasmin, 2013; Lukong et al., 
2008; Carninci, 2010). HuD is part of the ELAVl/Hu family of RBPs which have multiple 
functions, including stabilization and translation of its mRNA targets in neurons (Jain et 
al., 1997; Brennan and Steitz, 2001; Hinman and Lou, 2008; Pascale and Govoni, 
2012). Other functions include alternative splicing, alternative polyadenylation, and 
cytoplasmic shuttling (Bronicki and Jamin 2013). Characterization of certain HuD targets 
revealed the following sequence, X-U/C-U-X-X-U/C?-U-U/C, as a specific binding motif 
(Wang and Tanaka Hall, 2001). Appropriate regulation and protein expression may 
depend on a balance between binding to either destabilizing or stabilizing RBPs 
(Bronicki and Jasmin, 2013). This may be determined by the levels of the RBPs 
themselves but it may also be a function of which mRNA targets are present 
considering that destabilizing or stabilizing RBPs can bind the same target concurrently. 
This critical expression of certain mRNAs may be regulated by multiple processes, 
including mRNA degradation. mRNA degradation may be promoted by multiple 
processes itself, including binding by destabilizing RBPs that can result in mRNA 
deadenylation and degradation (Bronicki and Jasmin, 2014). Small noncoding 
microRNAs have also been shown to promote suppression of translation followed by 
mRNA degradation (Bronicki and Jasmin, 2014). HuD has been shown to bind longer 
poly(A) tails via its third RRM to promote cap-dependent translation (Fukao et al., 2009). 
It is possible that deadenylation may result in the inability of HuD to bind to a target 
bound by a destabilizing RBP.  Another possibility which has been observed is that a 
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lack of mTOR activity can result in mRNA decay by an unknown mechanism (Sosanya 
et al., 2013).  
 
HuD Regulation 
 HuD expression levels may be regulated by several mechanisms (Bronicki and 
Jasmin, 2013). Post-translational modifications of HuD is one such mechanism. Protein 
Kinase C (PKC) phosphorylation of HuD results in key localization and stabilization of its 
target, GAP-43 (Lim and Alkon, 2012; Pascale et al., 2005). Co-activator associated 
arginine methyltransferase 1 (CARM1) methylation of HuD inhibits its stabilization 
function of specific mRNAs (Bedford and Clarke, 2009; Fujiwara et al., 2006; Hubers et 
al., 2011). Recently, HuD has also been shown to be regulated by the miRNA, miR-375, 
and diminished mTOR activity results in decreased HuD expression (Abdelmohsen et 
al., 2010; Sosanya et al., 2013). Other mechanisms regulating HuD levels include 
transcriptional and post-transcriptional control (Bronicki and Jasmin, 2013). One of the 
targets of HuD is the microtubule binding protein, Tau, which has recently been shown 
to attenuate hyperexcitability in Kv1.1 KO mice (Holth et al., 2013). 
 
Epilepsy: HuD 
 Several recent studies have analyzed the expression of HuD and its targets in 
both the kainate and pilocarpine models of TLE. HuD levels and several of its target 
mRNAs increase expression in both models and dendritic localization of HuD increases 
following seizure development (Bolognani et al., 2007; Tiruchinapalli et al., 2008; 
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Winden et al., 2011). Our lab has also observed an increased expression of HuD and its 
target, Kv1.1, 5 days following SE (Sosanya et al., unpub.)  
 
microRNAs as Disease Biomarkers 
 Circulating microRNAs can remain in blood plasma, unlike their mRNA targets, 
due to the high stability of the Ago2-miRNA complex (Turchinovich et al., 2001). This 
raises the possibility of miRNAs as biomarkers for disease and diagnosis. Studies have 
shown that detection of certain circulating miRNAs can discriminate between certain 
cancers and healthy controls (Siddeek et al., 2014). Several microRNAs have been 
shown to be up- or down- regulated in the blood following certain injuries, including 24 
hr following kainate induced seizures (Liu et al., 2009; Jimenez-Mateos and Henshall, 
2013). It will be interesting to determine if miR-129 could be a potential disease marker 
for TLE to aid in determining possible disease progression and treatment. 
  
TLE Treatment: microRNAs  
 Forty percent of TLE patients are resistant to current treatment (Sharma et al., 
2007). MicroRNAs are playing an increasing role in several diseases including TLE. 
Recently, it has been reported that inhibition of a single microRNA, miR-134, was 
neuroprotective against damage from recurrent seizures (Jimenez-Mateos et al., 2012). 
Not surprisingly, microRNAs may have a significant effect on driving the molecular 
changes that occur immediately following status epilepticus (SE) as well as after the 
development of chronic recurring seizures. It is possible that miR-129 may regulate 
multiple targets in TLE and therefore knockdown of miR-129 would decrease seizure 
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activity by removing its suppressive effects on multiple targets. Knockdown of the 
microRNA, miR-134, in the CA3 region of the hippocampus prevented seizure activity, 
substantiating the idea that removing a single microRNA may have considerable effects 
on disease prevention due to its effect on multiple targets (Jimenez-Mateos et al., 
2012). 
 
Conclusion 
 Local translation is a fundamental process that can either help or hinder the 
progression of a disease. This is due to local translation underlying the expression of 
channels, receptors, and their key regulators, leading to either a stable or erratic 
neuron. Many neurological disorders are characterized by dysregulation of factors, RNA 
binding proteins and microRNAs, involved in regulating local translation, development, 
and plasticity. Regulatory balance is a requirement of any neurological system and 
these factors offer another area of potential targets for therapeutic intervention. We 
have only begun to understand how regulating RNA binding factors may prevent 
disease progression.  
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Chapter 2: Degradation of High Affinity HuD Targets Releases 
Kv1.1 mRNA from miR-129 Repression by mTORC1 
 
Introduction 
 
During learning and memory, neurons undergo changes in excitability to enhance 
their efficacy. One way to modulate neuronal excitability is through regulating the 
number and composition of ion channels expressed on the cell membrane (Kim and 
Hoffman, 2008; Zhang and Linden, 2003). Such regulation can be achieved through 
controlling the local translation of dendritic mRNAs to provide a rapid response to 
neuronal activity and ensure proper temporal and spatial expression. Our previous work 
has shown that the local dendritic translation of an ion channel, Kv1.1, mRNA is 
repressed by mTORC1 kinase activity (Raab-Graham et al., 2006). 
Kv1.1 is a dendrotoxin-sensitive voltage-gated potassium channel that is 
phylogenetically related to the Shaker channel in Drosophila (Hopkins et al., 1994; 
Tanouye and Ferrus, 1985). Kv1.1 is characterized as a delayed rectifier potassium 
channel that controls the frequency of the action potential (Brew et al., 2003). Unlike 
many ion channels that have redundant functions, Kv1.1 is essential. Mice lacking 
Kv1.1 either die early or have frequent spontaneous seizures (Smart et al., 1998). 
Furthermore, haploid insufficiency leads to episodic ataxia, a human neurological 
disease caused by mutations in Kv1.1 (Zerr et al., 1998). While a dendrotoxin-sensitive 
Kv current has been described in CA1 pyramidal dendrites, the molecular identity of this 
current remains inconclusive (Chen and Johnston, 2010; Golding et al., 1999; Metz et 
al., 2007; Storm, 1988). Moreover, prior to our report describing NMDA/mTORC1-
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mediated suppression of Kv1.1 local translation in dendrites, Kv1.1 was considered to 
be only expressed in axons of hippocampal neurons (Chen and Johnston, 2010; Geiger 
and Jonas, 2000; Monaghan et al., 2001; Raab-Graham et al., 2006; Schechter, 1997; 
Southan and Owen, 1997). Here we report the molecular mechanism for the regulation 
of dendritic Kv1.1 mRNA translation. 
Mammalian Target of Rapamycin (mTOR) is a ubiquitous serine/threonine kinase 
that forms two unique complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC1 kinase promotes cap-dependent translation via phosphorylation 
of S6K and 4E-BP, molecules critical for translational initiation. In neurons, mTORC1 
kinase is activated by its upstream effectors, including neuronal receptors such as N-
methyl-D-aspartate receptors (NMDAR) through the signaling molecules PI3K, Akt, and 
tuberous sclerosis complex proteins 1 and 2 (Tsc1/2) (Costa-Mattioli et al., 2009; Klann 
and Dever, 2004; Raab-Graham et al., 2006). Electrophysiological studies have shown 
that mTORC1 kinase activity is required for long-term depression (LTD) and late long-
term potentiation (L-LTP) (Hoeffer and Klann, 2010; Ronesi and Huber, 2008; Volk et 
al., 2007). These persistent changes in excitatory neurotransmission have been widely 
accepted as a model for the cellular basis for learning and memory (Bliss and Lomo, 
1973).  
While mTORC1 kinase-dependent translational activation is well studied, how 
selective mRNAs undergo translational repression when mTORC1 kinase is active 
remains unclear. Translational repression can be achieved by mRNA binding molecules 
such as microRNAs (miRNAs) or RNA-binding proteins. miRNAs are ~18-25 nucleotide 
long, noncoding RNAs that bind to their target sequences in the 3’ untranslated region 
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(UTR) of mRNAs, resulting in reduced protein expression via translational silencing or 
mRNA degradation (Bartel, 2009; Filipowicz et al., 2008a; Konecna et al., 2009; Kosik, 
2006).  
How mRNA repression is relieved to mediate bidirectional protein expression in 
an activity dependent manner is an important question. It was first hypothesized that 
miRNAs could directly or indirectly affect RNA-binding proteins ability to interact with 
their mRNA targets (George and Tenenbaum, 2006). Since then a growing body of 
evidence suggests that RNA-binding proteins can displace miRNAs from their target 
mRNAs even when the binding sites are located many nucleotides apart (Kundu et al., 
2012; Meisner and Filipowicz, 2011; Srikantan et al., 2012; Xue et al., 2013).  
Here we report the identification of a miRNA, miR-129, and a RNA-binding 
protein, HuD, both of which reversibly bind Kv1.1 mRNA when mTORC1 kinase is 
active and inactive, respectively. Using a local translation assay, we determined that 
removal of the miR-129 site releases the mTORC1 dependent repression of Kv1.1 
mRNA translation. Furthermore, we provide evidence suggesting that HuD high affinity 
mRNA targets, such as CaMKIIα, GAP-43, and Homer1a, are degraded when mTORC1 
is inhibited, allowing HuD to switch targets and overcome miR-129 repression of Kv1.1 
mRNA.  
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Results 
 
mTORC1 Kinase Activity Does not Affect Kv1.1 mRNA Levels 
 Previously, we have shown that mTORC1 kinase activity in cortical and 
hippocampal neurons suppresses the local protein synthesis of Kv1.1 mRNA in 
neuronal dendrites (Raab-Graham et al., 2006). When mTORC1 kinase activity is 
inhibited by its specific inhibitor, rapamycin, a significant increase in dendritic Kv1.1 
protein is observed (Figure 2.1A; (Raab-Graham et al., 2006)). To determine the 
molecular mechanism for the change in Kv1.1 expression in dendrites we first assessed 
if there were corresponding changes in mRNA levels with mTORC1 activity. In cultured 
neurons (21 – 28 days in culture), mTORC1 kinase is phosphorylated and thus 
constitutively active (Figure 2.1A). Synaptoneurosomal (SN) preparation was checked 
for purity by western blot and immunostaining with nuclear marker (Figure S2.1A). 
Treatment with rapamycin inhibits mTORC1 kinase activity by reducing the active p-
mTOR over total mTOR ratio to 59.20±4.67% and leads to a ~2 fold increase in Kv1.1 
protein (Figure 2.1A; Kv1.1: DMSO 1.00±0.18; Rapa 2.00±0.26; (Raab-Graham et al., 
2006). We next examined the mRNA levels in SN isolated from cortical neurons treated 
with rapamycin or carrier (DMSO) by quantitative real-time polymerase chain reaction 
(qPCR). The representative gel indicates the amplification of a specific Kv1.1 product 
for each condition (Figure 2.1B, above). Independent of mTORC1 kinase activity, the 
mRNA level remains constant (Figure 2.1B, bar graph), suggesting a mechanism of 
altered translation rather than changes in mRNA transport or degradation.  
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Kv1.1 3’UTR Is Required for mTORC1 Kinase-dependent Translational Repression  
To investigate the molecular mechanism of such translational repression, we first 
searched for potential regulatory sequences in Kv1.1 mRNA that confer mTORC1 
kinase-sensitive repression (Raab-Graham et al., 2006). Previously, we showed local 
translation of Kv1.1 when mTORC1 kinase is inhibited by blocking N-Methyl-D-
aspartate receptors (NMDAR) or by the mTORC1 specific inhibitor rapamycin using the 
construct containing the coding region (CR) plus the 230 nucleotide (nt) 3’UTR of Kv1.1, 
cloned from synaptoneurosomal cDNA (Raab-Graham et al., 2006). Based on this 
finding, we hypothesized that a putative mTORC1 kinase repression sequence (mTRS) 
was present within this 3’UTR.  
 To verify the importance of the mTRS for Kv1.1 translation in neurons, we 
designed a competition assay in which excess 3’UTR was introduced to compete for the 
binding of factors that suppress endogenous Kv1.1, thus resulting in increased Kv1.1 
expression (Figure S2.1). Exogenous 3’UTR containing the putative mTRS was 
introduced into neurons by a Sindbis virus coding for the fluorescent protein Kaede 
(Ando et al., 2002) fused to the 3’UTR. To control for nonspecific effects due to viral 
infection, neurons were infected with virus coding for Kaede fused to the dendritic 
targeting sequence (DTS) of MAP2 (Figure 2.2B; morphological similarity between 
neurons is demonstrated in Figure S2.1B; (Blichenberg et al., 1999)). The level of 
surface Kv1.1 protein was determined by immunocytochemistry on non-permeabilized 
neurons using an antibody that recognizes the extracellular domain of Kv1.1 (Raab-
Graham et al., 2006; Tiffany et al., 2000). As expected, excess 3’UTR containing the 
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putative mTRS of Kv1.1 mRNA released endogenous Kv1.1 mRNA from repression, 
resulting in a ~5 fold (5.41±0.99) increase in Kv1.1 surface protein expression in the 
dendrites as determined by signal intensity of punctate structures with no significant 
change in the soma (Figure 2.2B; Figure S2.1C). Such an increase is comparable to the 
levels observed when mTORC1 kinase is inhibited by rapamycin, and excess mTRS 
does not further increase Kv1.1 expression in rapamycin treated neurons (Figure 2.2B). 
Collectively, these data suggest that the putative mTRS within the 3’UTR is required for 
repressing Kv1.1 translation in an mTORC1 kinase-sensitive manner.  
 
miR-129 Binds Kv1.1 mRNA in an mTORC1 Kinase-dependent Manner 
Notably, sequence alignment of the 3’ UTR containing the mTRS with other 
mammalian Kv1.1 UTRs revealed a conserved binding site (or seed match sequence) 
for the microRNA, miR-129 (Figure 2.3A). Consistent with Kv1.1 mRNA levels 
remaining constant with changes in mTOR activity, the complementary of the miR-129 
binding site to the 3’ UTR sequence is considered to be weak, favoring a role in 
translational repression over degradation (Filipowicz et al., 2008). To determine if miR-
129 binds to Kv1.1 mRNA and perhaps mediates the mTOR dependent-repression, we 
utilized an RNA affinity capture system (Kuwano et al., 2008). RNA was synthesized by 
in vitro transcription of cDNAs coding for Kv1.1:  full-length (FL; coding region + 3’UTR), 
coding region (CR), or full-length with the predicted miR-129 binding site (seed match 
sequence) mutated to the complementary sequence (∆miR-129) (Figure 2.3B, above). 
The purified RNAs were then labeled with a biotin-linked oligonucleotide and served as 
bait to pull down binding factors from neuronal lysates harvested from cultured cortical 
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neurons treated with DMSO or rapamycin. Factors that bound to Kv1.1 RNA were then 
precipitated with streptavidin-coated magnetic beads and examined by qPCR for the 
presence of miR-129 (Figure S2.2A). 
When mTORC1 kinase is active and Kv1.1 mRNA translation is suppressed, 
miR-129 was bound to the full-length RNA (Figure 2.3B, bar graph). As a negative 
control, the RNA affinity capture assay was carried out using in vitro synthesized RNA 
encoding the coding region alone (CR) or the full-length RNA with a mutated miR-129 
binding site (ΔmiR-129). As expected, miR-129 binding was significantly reduced under 
both control conditions relative to the binding of the full-length RNA (CR: 11±9%, 
DMSO; ∆miR-129: 6±5%, DMSO). However, when mTORC1 kinase was inhibited with 
rapamycin, miR-129 binding to the full-length RNA was reduced to 45±15% (Figure 
2.3B). This level was not different from the background binding detected by the two 
constructs missing the miR-129 seed match sequence. Melt curve analysis was 
performed to verify that one product was amplified for miR-129 with a signature melting 
temperature determined by the input (Figure S2.2B). Similar to what we observed in 
cultured neurons, using solubilized synaptoneurosomes isolated from rat cortices, the 
full-length RNA bound significantly more miR-129 than the coding region RNA (52±1% 
relative to full-length; Figure S2.2C). These results suggest that miR-129 binds to the 
3’UTR of Kv1.1 mRNA when mTORC1 kinase is active.  
 
miR-129 Knockdown in Neurons Increases Kv1.1 Expression  
We next examined the effect of miR-129 on Kv1.1 expression in neurons by 
transfecting a locked nucleic acid (LNA) probe complementary to miR-129 to knock 
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down (KD) its level in neurons. Total Kv1.1 protein was then determined by 
immunocytochemistry. The protein levels of another dendritic potassium channel, Kv4.2, 
were determined as a control. The effectiveness of miR-129 knockdown was 
established in cortical neurons showing a reduction in miR-129 levels by northern blot 
and an increase in the published miR-129 target, ERK2 (Figure S2.2D; (Wu et al., 
2010)). If miR-129 suppresses the translation of Kv1.1 in dendrites, then knocking down 
miR-129 will increase the expression of Kv1.1. Indeed, we observed a significant 2-3 
fold increase in signal intensity of Kv1.1 punctate structures in dendrites when miR-129 
was knocked down compared to the negative EGFP or the scrambled LNA controls 
(Figure 2.3C, miR-129 KD vs. EGFP, 2.95±0.3; miR-129 KD vs. Scrambled LNA, 
1.9±0.12, Figure S2.2E). Moreover, there was no change in Kv1.1 intensity in the cell 
body when miR-129 was knocked down (Figure S2.2E). Furthermore, no significant 
change was observed in dendritic staining for Kv4.2 (Figure 2.3D and S2.2E). These 
data suggest that miR-129 suppresses the translation of Kv1.1 mRNA in neuronal 
dendrites.  
 
Overexpression of miR-129 Represses Kv1.1 mRNA Translation When mTORC1 
Kinase is Inhibited  
To test whether miR-129 mediates repression of Kv1.1 mRNA translation when 
mTORC1 kinase is active, we transduced neurons with a lentivirus coding for a 
precursor form of miR-129 (pre-miR-129-2). We predicted that increasing the level of 
miR-129 would mimic mTORC1 repression of Kv1.1 mRNA translation and thus prevent 
the increase in dendritic Kv1.1 expression when mTORC1 kinase is inhibited. Indeed, 
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overexpression of miR-129 prevents the observed increase in Kv1.1 dendritic protein 
with rapamycin, maintaining levels similar to the mTORC1 kinase active state (Figure 
2.3E, Figure S.22F). These data suggest that miR-129 binding to Kv1.1 mRNA is 
necessary for repressing Kv1.1 translation when mTORC1 is active.  
 
Repression of Local Protein Synthesis of Kv1.1 mRNA in Neurons is Relieved 
When the miR-129 Binding Site is Mutated  
To further test the functional role of miR-129 in the regulation of Kv1.1 mRNA 
translation, we performed a local translation assay using Kaede fused to Kv1.1 as a 
translational reporter (Raab-Graham et al., 2006). Kaede is a fluorescent protein that 
changes color from green to red upon UV-induced photoconversion (Ando et al., 2002). 
To assess new protein synthesis, pre-existent Kaede-fused protein is first 
photoconverted to red, and newly synthesized green protein can thus be monitored and 
quantitated over time. Neurons expressing Kaede-Kv1.1 mRNA with either intact mTRS 
or with the predicted miR-129 binding site (seed match) sequence mutated (∆miR-129) 
were imaged for two hours after complete photoconversion. Detection of new “green” 
Kaede-Kv1.1 indicates Kv1.1 mRNA translation (Raab-Graham et al., 2006). Previously, 
we have shown that Kv1.1 protein appears in hot spots within the dendrite when 
mTORC1 kinase is inhibited. Furthermore, Kv1.1 was found to remain stationary within 
these hot spots. Transport rates were measured to be less than 15 µm per hour (Raab-
Graham et al., 2006). Based on these data, we analyzed only new green Kaede-Kv1.1 
puncta greater than 60 µm from the cell body to ensure all new protein was locally 
synthesized.   
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Z-stack images detecting the green signal were acquired over time and 
pseudocolored to reflect the signal intensity of newly synthesized green Kaede-Kv1.1 
protein. As shown in Figure 2.4, mutating the miR-129 site in the 3’UTR of Kv1.1 mRNA 
results in an increase in Kv1.1 local mRNA translation by ~ 200% (215.1± 22.57%) 
when mTORC1 kinase was active, similar to the signal observed in neurons expressing 
Kaede-Kv1.1 with an intact miR-129 site when mTORC1 kinase is inhibited with 
rapamycin. Furthermore, in the absence of the miR-129 site, rapamycin treatment did 
not result in further increased translation, suggesting that the miR-129 binding site is the 
mTOR repressive sequence. 
 
Binding of miR-129 Leads to Repression Rather than Degradation of Kv1.1 mRNA 
in Neuronal Dendrites 
MicroRNAs have reported roles in both the repression and the degradation of 
their target mRNAs (Fabian et al., 2010). To verify that miR-129 represses translation 
without altering mRNA stability, we performed an in situ hybridization using an 
antisense oligo against EGFP (Raab-Graham et al., 2006; Wells et al., 2001) on 
neurons expressing EGFP fused to Kv1.1 with either an intact or mutated miR-129 
binding site (Figure 2.5). If miR-129 binding leads to the degradation of Kv1.1 mRNA, 
we would predict that more RNA will be detected with the removal of the miR-129 
binding site. However, if miR-129 binding represses Kv1.1 mRNA without degradation, 
then removal of the miR-129 site will lead to increased protein expression without 
altering mRNA levels. As expected, the overall RNA steady-state levels were the same 
between the two sets of neurons (FL, 1.0±0.06; ΔmiR-129, 1.1±0.06; Figure S2.3A), 
21 
 
whereas more protein was detected in the dendrites expressing Kv1.1 with the mutated 
sequence, as indicated by the ratio of EGFP/in situ hybridization signal (Figure 2.5 and 
Figure S2.3B: FL, 1.0±0.06; ΔmiR-129, 1.4±0.09). Considering that Kv1.1 mRNA level 
remains constant independent of mTORC1 kinase activity (Figure 2.1B) and that 
mutation of the miR-129 binding site does not change mRNA stability, these data thus 
support a mechanism of microRNA-mediated repression over degradation. 
 
HuD Binds Kv1.1 mRNA when mTORC1 Kinase is Inactive and Overrides 
mTORC1 Kinase-dependent Repression 
 During neuronal transmission, signaling through the NMDA-R via the 
PI3K/mTORC1 pathway represses Kv1.1 mRNA translation. Although such translational 
repression of Kv1.1 may lead to increased excitability and provide an important positive 
feedback mechanism for learning and memory, homeostatic mechanisms that lower the 
membrane potential are required to maintain neuronal stability and allow new learning 
to occur (Davis and Goodman, 1998; Turrigiano and Nelson, 2000). Since we identified 
miR-129 as the translational repressor of Kv1.1 mRNA when mTORC1 kinase is active, 
how inactivating mTORC1 kinase with rapamycin releases such translational repression 
became the next question.  
We first asked whether miR-129 levels would decrease upon rapamycin 
treatment, thus limiting the amount available to repress translation. To test this 
possibility, we performed qPCR to detect miR-129 in synaptoneurosomal RNA isolated 
from neurons where mTORC1 kinase was active (control, DMSO) or inhibited by 
rapamycin. Contrary to our prediction, we did not observe a significant change in miR-
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129 levels between control and rapamycin treated neurons as determined by both RT-
qPCR and northern blot (Figure 2.6A).   
An alternative possibility is that additional factor(s) interact with Kv1.1 mRNA to 
relieve repression and promote translation when mTORC1 kinase is inhibited. We 
therefore searched for RNA-binding proteins that bind Kv1.1 mRNA in an mTORC1 
kinase-sensitive manner.  To find such candidates, we performed a bioinformatic scan 
for known binding sites for RNA-binding proteins within the full-length Kv1.1 mRNA. We 
identified 3 putative HuD-binding sites in the coding region of Kv1.1 mRNA (Figure 
S2.4A), consistent with a HuD binding motif previously reported by Wang and Tanaka-
Hall (x-U/C-U-x-x-U/C-U-U/C; Figure S2.4A; (Wang and Tanaka Hall, 2001)). The Hu 
family of RNA-binding proteins has an established role in stabilizing mRNAs, promoting 
translation, and has been shown to be important for dendritic protein synthesis (Antic et 
al., 1999; Bolognani and Perrone-Bizzozero, 2008; Fukao et al., 2009; Tiruchinapalli et 
al., 2008). Moreover, similar to inhibiting mTORC1 kinase with rapamycin to prevent 
consolidation, mice that overexpress HuD have deficits in learning and memory 
(Bolognani et al., 2007). 
To verify the predicted binding of HuD to Kv1.1mRNA, coimmunoprecipitation 
(co-IP) of transfected HEK cells was used to assess if HuD binds directly to Kv1.1 
mRNA. HEK cells were co-transfected with myc-tagged HuD plus either Kaede-Kv1.1 
full-length, Kaede-Kv1.1 coding region, or Kaede-Kv1.1 ∆miR-129. mRNA protein 
complexes (mRNPs) containing HuD were immunoprecipitated from lysates using a 
myc specific antibody. Bound Kv1.1 mRNAs were then detected by RT-PCR using 
Kv1.1 specific primers. To control for antibody specificity, HEK cells were transfected 
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with Kaede-Kv1.1 and an empty vector without myc-HuD. We also included a negative 
control for nonspecific PCR amplification using myc-HuD and Kaede alone. As 
expected, Kaede-Kv1.1 full-length, coding region, and ∆miR-129 mRNA all copurified 
with HuD protein (Figure 2.6B). This result is consistent with the predicted HuD binding 
elements found within the coding region of Kv1.1 mRNA (Figure S2.4A). Additionally, 
Kv1.1 specific PCR products were only detected from RNA immunoprecipitated from 
lysates expressing HuD and Kv1.1 (Figure 2.6B). Collectively, these results suggest that 
HuD binds to the coding region of Kv1.1 mRNA. A similar mechanism was recently 
shown for another member of the Hu protein family, HuR, which was found to displace 
miRISCs from target mRNAs even when its binding site and the miRNA site were not 
adjacent (Kundu et al., 2012). 
A direct prediction of this hypothesis is that increasing HuD protein when 
mTORC1 kinase is active will overcome miR-129 mediated repression of Kv1.1 mRNA. 
To test this, we overexpressed HuD in cultured hippocampal neurons and measured 
dendritic Kv1.1 protein. Figure 2.6C shows that under conditions where mTORC1 
kinase is active, neurons overexpressing HuD show a significant 3-4 fold (3.7±0.41) 
increase of Kv1.1 punctal intensity in dendrites with no significant change in Kv1.1 
levels in the cell body (Figure S2.4B). Kv4.2 signal is not affected by HuD 
overexpression. This increase in Kv1.1 punctal signal is specifically inhibited by the 
presence of the well characterized protein synthesis inhibitor cycloheximide (0.3±0.04).  
Notably, cycloheximide further decreases the levels of both Kv1.1 and Kv4.2 relative to 
the control condition, indicating a decrease in basal translation (Kv1.1, 0.3±0.04; Kv4.2, 
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0.4±0.05). These results suggest that overexpression of HuD overrides mTORC1 
kinase/miR-129 dependent repression of Kv1.1 mRNA translation. 
We next tested whether HuD binding to Kv1.1 mRNA is altered with mTORC1 
kinase activity. Purified GST-HuD fusion protein was incubated with total RNA isolated 
from carrier DMSO or rapamycin treated neurons and immunoprecipitated with a pan 
Hu antibody (Deschenes-Furry et al., 2007). Bound Kv1.1 mRNAs were then detected 
by RT-PCR with gene specific primers. GAP-43 and CaMKIIα mRNAs, known targets of 
HuD (Bolognani et al., 2010; Bolognani et al., 2006; Tiruchinapalli et al., 2008), were 
also assayed in parallel as controls.  The differential binding of HuD with different 
mTORC1 activity to the three mRNAs assayed is reflected by the quantified ratio of 
mRNA pulled down in rapamycin over DMSO, as shown in Figure 2.6D (Note: a ratio of 
one indicates equal binding under both conditions, a ratio greater than one favors 
binding in the presence of rapamycin, a ratio less than one favors binding in DMSO). 
Interestingly, HuD only binds to GAP-43 mRNA in neurons treated with DMSO (Figure 
2.6D, rapamycin/DMSO ratio significantly smaller than 1, one sample t-test, p<0.05) 
whereas HuD binds CaMKIIα mRNA under both conditions (Figure 2.6D, 
rapamycin/DMSO bound ratio = 1.4 ± 0.4 S.D. and was not considered significant from 
1 by a one-sample t-test). In contrast, HuD only binds Kv1.1 mRNA in neurons treated 
with rapamycin (Figure 2.6D, with a ratio 8.6 ± 0.7 S.D., one sample t-test, p<0.05). The 
result that HuD only binds Kv1.1 mRNA in neurons treated with rapamycin supports a 
role for HuD in promoting Kv1.1 mRNA translation when mTORC1 is inhibited. 
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HuD Binding to Kv1.1 mRNA Coincides with the Reduced Level of Other HuD 
Target mRNAs 
We next asked whether HuD protein levels increase with mTORC1 kinase 
inhibition which could lead to enhanced dendritic Kv1.1 levels. Western blot analysis 
using a HuD specific antibody was carried out on DMSO or rapamycin treated 
synaptoneurosomes. Contrary to what we expected, HuD levels significantly decrease 
when mTORC1 was inhibited (DMSO: 1.00±0.06; Rapa: 0.63±0.09; Figure 2.7A). 
We then considered the possible relationship between mTORC1 activity and the 
abundance of other HuD targets. Notably in Figure 2.6D, the total input of the high 
affinity HuD target CaMKIIα with 32 predicted binding sites, some of which overlap 
(Bolognani et al., 2010), appears to be reduced when mTORC1 kinase is inhibited with 
rapamycin. To verify this observation in a quantitative manner, we performed RT-qPCR 
for CaMKIIα and Kv1.1 mRNAs by isolating total RNA from neurons treated with DMSO 
or rapamycin. As expected, CaMKIIα mRNA was reduced by ~70% when mTORC1 
kinase was inhibited with rapamycin (rapamycin, 33.6±12.5% of control).  Furthermore, 
when we assessed the relative abundance of two additional HuD targets, GAP-43 and 
Homer1a, we found they were both reduced by ~40% and were significantly different 
from control (GAP-43: rapamycin, 58.9±14% of control; Homer1a: rapamycin 59±12% of 
control; Figure 2.7B). In contrast, Kv1.1 mRNA levels remained the same between the 
two conditions (Kv1.1: rapamycin 89±27% of control; Figure 2.6D, input and Figure 
2.7B). Moreover, the reduction of CaMKIIα mRNA is also reflected by the reduced 
protein level when mTORC1 kinase is inhibited (Figure 2.7C). Collectively, these data 
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led us to consider the possibility that HuD switches its targets in accordance with the 
mRNAs that are available to be translated.  
To determine whether mTORC1 activity affects high affinity HuD target mRNAs 
levels at the transcriptional level or causes mRNA degradation, we treated neurons with 
the transcriptional inhibitor actinomycin for four hours prior to inhibiting mTORC1 activity 
with rapamycin and determined the mRNA levels of CaMKIIα. We predicted that if 
mTORC1 activity regulates the transcription of CaMKIIα, then pretreatment with 
actinomycin will reflect the same changes in mRNA levels as observed with rapamycin 
treatment alone. However, if inhibition of mTORC1 kinase activity by rapamycin 
promotes the degradation of CaMKIIα mRNA, rapamycin treatment in the presence of a 
transcriptional inhibitor will further decrease the amount of CaMKIIα mRNA. As shown in 
Figure 2.7D, quantitative PCR analysis of CaMKIIα mRNA levels showed a reduction by 
61% (actinomycin, 100±0.9%; actinomycin+rapamycin, 39 ±18.3%) in neurons treated 
with both actinomycin and rapamycin relative to actinomycin alone, supporting CaMKIIα 
mRNA degradation over altered transcription upon mTORC1 inhibition (Figure 2.7D). 
Overexpression of CaMKIIα UTRs Prevents the Increase in Dendritic Kv1.1 
Protein when mTORC1 Kinase is Inhibited 
 If HuD binding to Kv1.1 mRNA requires the degradation of high affinity targets 
such as CaMKIIα mRNA, overexpression of CaMKIIα mRNA containing several HuD 
binding sites may affect the dendritic expression of Kv1.1 protein. We tested this 
prediction by overexpressing GFP-fused UTRs of CaMKIIα (5’UTR-GFP-3’UTR of 
CaMKIIα) (Aakalu et al., 2001) in neurons and measured the resulting dendritic Kv1.1 
protein levels. The overexpressed CaMKIIα 3’ UTR is predicted to carry 8 overlapping 
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HuD binding sites (Figure S2.4C). The ability of HuD to promote translation of this 
construct was first tested in HEK cells. Coexpression of HuD and GFP-CaMKIIα UTRs 
demonstrated a functional interaction by increasing the expression of GFP by ~3 fold 
over GFP-CaMKIIα UTRs alone (vector only control, 1.00±0.26; HuD, 3.24±0.59; Figure 
S2.4D). We then tested whether providing excess CaMKIIα UTRs for HuD binding in 
neurons will prevent the observed increase in Kv1.1 protein with mTORC1 kinase 
inhibition. Indeed, dendritic Kv1.1 protein levels no longer increased with rapamycin 
treatment in the presence of excess CaMKIIα UTRs (Figure 2.8A, GFP+DMSO, 
1.00±0.12; GFP+rapamycin, 1.58±0.11; CaMKIIα UTRs+DMSO, 1.13±0.14; CaMKIIα 
UTRs+rapamycin, 0.88±0.11). To verify that repression of Kv1.1 mRNA translation with 
excess CaMKIIα UTR in the presence of rapamycin is due to HuD binding this 
construct, we removed the predicted HuD binding sites within the 3’ UTR (CaMKIIα 
UTR∆HuD) by PCR based deletion. Indeed, with mTORC1 inhibition, dendritic Kv1.1 
protein expression was restored and insensitive to overexpression of CaMKIIα 
UTR∆HuD relative to neurons expressing CaMKIIα UTR (Figure 2.8B, CaMKIIα UTRs 
+DMSO, 1.00±0.09; CaMKIIα UTRs +rapamycin, 1.36±0.11;  CaMKIIα UTRs∆HuD 
+DMSO, 1.24±12; CaMKIIα UTRs∆HuD +rapamycin, 2.48±0.21). These results suggest 
that CaMKIIα and Kv1.1 mRNAs compete for HuD binding enabling translation. 
Collectively, our results support the hypothesis that mTORC1 kinase affects Kv1.1 
mRNA translation by changing the availability of HuD via degradation of other high 
affinity HuD target mRNAs. 
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Discussion 
 
Reversible binding of RNA-binding Factors to Kv1.1 mRNA with mTORC1 Activity 
Regulates Dendritic Expression of  Kv1.1 
mTORC1 regulation of Kv1.1 mRNA translation provides an example for how 
RNA-binding factors may determine the bidirectional expression of dendritic ion 
channels. As depicted in Figure S2.5, our findings support a model where the levels of 
Kv1.1 expression can be titrated by the interplay between mTORC1 kinase-dependent 
reversible binding of miR-129 and HuD to Kv1.1 mRNA. We have provided several lines 
of evidence demonstrating the repressive role of miR-129. We found that miR-129 binds 
to Kv1.1 mTRS only when mTORC1 kinase is active and knocking down miR-129 in 
neurons increases Kv1.1 expression in dendrites; whereas overexpressing miR-129 
prevents the rapamycin dependent increase in dendritic Kv1.1. Consistent with these 
results, mutating the miR-129 binding site released the local translation of Kv1.1 mRNA 
from mTORC1 kinase mediated repression. All these data suggest that NMDAR 
activation (Raab-Graham et al., 2006) and mTORC1 kinase signaling may lead to a 
positive feedback mechanism that reduces the expression of Kv1.1 channels via miR-
129, perhaps rendering the dendrite more excitable (Figure S2.5, left dendrite). 
A major concern of a positive feedback loop is that if left unchecked it will lead to 
neuronal instability and prevent further acquisition of new information (Turrigiano and 
Nelson, 2000). Our findings support a homeostatic mechanism to possibly reduce 
dendritic excitability by increasing Kv1.1 mRNA translation via the RNA-binding protein, 
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HuD. We found that expression of dendritic Kv1.1 is determined by mTORC1 kinase-
dependent availability of HuD for Kv1.1 mRNA in the dendrite. We show that HuD binds 
to high affinity mRNA targets, such as CaMKIIα mRNA, when mTORC1 kinase is active. 
Those mRNAs degrade when mTORC1 kinase is inhibited, thus releasing HuD to bind 
to the coding region of Kv1.1 mRNA and possibly releasing miR-129-containing miRISC 
from the 3’ UTR of this mRNA. Furthermore, neurons overexpressing HuD show protein 
synthesis-dependent increase of Kv1.1 expression. We thus propose that HuD binds to 
Kv1.1 mRNA when mTORC1 kinase is inhibited and promotes its translation (Figure 
S2.5, right dendrite). Collectively, our results suggest that mTORC1 kinase serves as a 
molecular switch for bidirectional changes in dendritic expression of Kv1.1.  
 One surprising and novel finding from our data is that mTORC1 kinase activity 
affects the degradation of high affinity HuD mRNA targets, such as CaMKIIα, GAP-43 
and Homer1a, instead of affecting miR-129 or HuD levels to favor Kv1.1 mRNA binding. 
In yeast, rapid degradation of some mRNAs, but not all, has been reported with nutrient 
limitation or TORC1 kinase inhibition by accelerating the deadenylation-decapping 
pathway (Albig and Decker, 2001). To our knowledge, our study is the first example of 
mRNA degradation serving as a way to recycle RNA-binding factors and thus promote 
the translation of other targets. Consistent with a recycling mechanism, overexpression 
of CaMKIIα UTRs occludes the increase in dendritic Kv1.1 protein in rapamycin treated 
neurons. Furthermore, with mTORC1 inhibition, CaMKIIα UTRs with the HuD binding 
sites removed rescued this reduction of endogenous dendritic Kv1.1. Our results thus 
suggest that changing the local availability of the regulatory factors may provide a rapid 
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and spatially restricted response, therefore bypassing the need for new transcription or 
translation of those factors.  
miR-129 and HuD may be Important Regulators of Memory and Disease mediated 
by mTORC1 activity 
The importance of miRNAs in neuronal development and plasticity is emerging 
(Kosik, 2006; Schratt, 2009). miR-129 has been identified to be specifically enriched in 
the brain (Kim et al., 2004; Landgraf et al., 2007; Miska et al., 2004); however, its role in 
neuronal function has not been identified. Our data reveal that miR-129 represses the 
expression of Kv1.1 when mTORC1 is active, which may partially contribute to the 
increased risk for seizures in disease states with hyperactive mTORC1 kinase (Sahin, 
2012; Sharma et al., 2010; Zeng et al., 2009). 
The discovery of mTORC1 mediated switching of HuD binding targets provides 
clues for the importance of mTORC1 in memory. As memory requires both the induction 
of positive regulators, (such as CaMKIIα that can enhance synaptic strength), and the 
removal of negative constraints (Abel et al., 1998), (such as potassium channels that 
can dampen action potentials), translational control of those regulators by HuD via 
mTORC1 mediated mRNA degradation is thus conceivably important for memory. Our 
findings may thus explain why HuD has been found to be important for memory 
(Bolognani et al., 2004; Pascale et al., 2004), but overproduction of HuD in transgenic 
mouse led to memory deficits (Bolognani et al., 2007). In other words, the physiological 
role of HuD may be determined by the ratio of available high to low affinity targets such 
as CaMKIIα and Kv1.1, respectively. 
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 Since hundreds of dendritic mRNAs have been identified (Martin and Zukin, 
2006) and Kv1.1 was the first example of a voltage-gated ion channel being locally 
translated (Raab-Graham et al., 2006), other mRNAs that are critical to site-specific 
changes in dendritic excitability may utilize the same mechanism to regulate their local 
translation. Our study may thus lead to the future discovery of other functionally related 
mRNAs suppressed by mTORC1 kinase activity. Moreover, Kv1.1, miR-129, and HuD 
may serve as important targets and/or biomarkers for mTORC1 kinase-related diseases 
such as epilepsy, Fragile X Syndrome, Tuberous sclerosis complex and Alzheimer’s 
disease (Richter and Klann, 2009; Sharma et al., 2010).  
 
Materials and Methods 
 
Antibodies Used 
Primary antibodies: mouse anti-NeuN (1:500, Millipore), mouse anti-Kv1.1 extracellular, 
1:1000 (Neuromab 75-105), mouse anti-Kv1.1, 1:1000 (Neuromab 75-007), mouse anti-
Kv4.2 (Neuromab 75-016), rabbit anti-Kaede, 1:500 (MBL PM012), rabbit anti-Phospho 
mTOR, 1:500 (Cell Signaling 2971S), mouse anti-tubulin, 1:1000 (Sigma-Aldrich 
T6074); rabbit anti-HuD, 1:1000 (Millipore AB5971; epitope: 26-42 nt), rabbit anti-ERK2, 
1:1000 (Cell Signaling Technology, 9108S) rabbit anti-myc 1:150 (Sigma-Aldrich 
c3956), rabbit anti-GFP 1:1000 (Abcam ab6556), rabbit anti-HuD (Santa Cruz, sc-
25360, for GST pulldown). Western blot signals were detected by secondary antibodies 
conjugated to HRP (1:1000, Jackson labs) for chemilluminescence or IR conjugated 
32 
 
 
secondary antibodies (1:5000, IR680; 1:5000, IR800) for Licor Infrared Imaging system. 
For immunostaining, secondary antibodies conjugated to either Alexa-488 (1:400, 
Invitrogen), Cy3 (1:500, Jackson labs), Alexa 647 (1:200, Invitrogen) or Cy5 (1:200, 
Jackson labs) were used.  
 
Preparation of Primary Cultured Neurons 
Primary neurons were prepared as previously described (Ma et al., 2002). Briefly, 
cortices from E18-19 rats were collected, dissociated, and plated. Neurons were plated 
at densities of 15 million neurons/100 mm dish for affinity RNA capture experiments, 2 
million/35 mm well for western blot and qPCR, 400,000 neurons/12 mm coverslip for 
imaging in figure 2.2 and 200,000 neurons/12 mm coverslip for imaging in figure 2.3. 
 
Isolation of Synaptoneurosomes (SN) and neuronal lysates 
SN were isolated by a modified method as previously described (Quinlan et al., 1999). 
Briefly, neurons were harvested in buffer B (20 mM HEPES, pH 7.4, 5 mM EDTA, pH 
8.0, protease inhibitor cocktail (Complete, Roche), phosphatase inhibitor, RNase 
inhibitor Superase-In (Ambion) or RNaseOut (Invitrogen) at 40 units/ml) and 
homogenized. After pelleting nuclei and unbroken cells at 80x g for 10 min, the 
supernatant was filtered first through a sterile 100 µm nylon filter followed by a 5 m 
filter. SN was pelleted at 14,000xg for 20 min. For mRNA quantification, total RNA was 
isolated using RNeasy columns as outlined by the manufacturer (Qiagen). For miRNA 
experiments, total RNA was isolated using TRI Reagent (Applied Biosystems). For RNA 
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affinity capture, SN pellet was solubilized with RIPA buffer (150 mM NaCl, 10 mM Tris, 
pH 7.4, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA supplemented with 
protease inhibitor cocktail tablet and RNase inhibitor) at 4°C overnight and centrifuged 
at 55,000xg for 1 hour to remove any insoluble aggregates. For neuronal lysates, DIV21 
cultured cortical neurons were harvested, homogenized and centrifuged similarly as SN 
without further filtrations or centrifugation. The supernatant after removing P1 pellet was 
collected and used for RNA affinity capture experiments. 
 
Measure SN purity 
Prior to SN preparation, an aliquot was removed and served as total lysate. Total and 
concentrated SN was smeared directly onto glass slides, fixed, permeabilized and then 
stained using DAPI (1:1000) wash in PBS. Imaged using 20x objective. This staining 
method was adapted from Williams et al., 2009. 
 
Sindbis virus generation 
All the constructs listed below were subcloned into SinRep5 virus vector (Invitrogen) 
and pseudovirions produced according to the manufacturer’s directions. 
Kaede-Kv1.1-mTRS: Kaede-Kv1.1 in the SinRep5 vector was digested with Bcl I. The 
region of DNA between nucleotide 153 and 1477 (accession number M26161) was 
dropped out. The backbone DNA was religated. 
Kaede-Map2-dendritic targeting sequence (DTS): The 3’UTR of MAP2 between 
nucleotide 2418 and 3096 (accession number U30938) was cloned by PCR using 
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specific primers including a Not I restriction site in the forward primer and an Xba I site 
in the reverse primer (listed in the primers section) (Blichenberg et al., 1999). The PCR 
product was digested with Not I and Xba I and ligated into the corresponding restriction 
sites within the multiple cloning site after the stop codon of Kaede in the Living Color 
vector (Clontech). Kaede-MAP2-DTS was subcloned into the SinRep5 vector by a blunt 
end ligation.  
Kaede-Kv1.1 and EGFP-Kv1.1 FL and ΔmiR-129: Kaede or EGFP fused to full length 
Kv1.1 coding region and mTRS were previously cloned into pCDNA3 as described in 
Raab-Graham et. al., 2006. Mutation of miR-129 binding site (seed match sequence) 
was then achieved by performing Quick Change Site Directed Mutagenesis 
(Stratagene) using primers 5’caaaaccaaccaaacaacgtttttgaaaaaaaaaacccaac3’ and 
5’gttgggttttttttttcaaaaacgttgtttggttggttttg3’ (mutations indicated as underlined sequence). 
The resulting constructs were then subcloned into SinRep5 vector for virus production. 
 
Competition Assays 
For figure 2.2, DIV21 cortical neurons were infected with Sindbis virus coding for 
Kaede-MAP2-DTS (control) or Kaede-Kv1.1-mTRS. 18 hours post infection, neurons 
were treated with DMSO or rapamycin (200 nM) in HEPES based aCSF for 75 min at 
37°C. Following treatment, neurons were fixed with 4% paraformaldehyde for 10 min on 
ice. Neurons were immunostained and imaged as outlined in immunofluorescence 
section. Surface expression was quantitated by blindly choosing Kaede positive 
neurons. 
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For Figure 2.8, CaMKIIα 5’- 3’UTR fused to destabilized GFP (dGFP- 5’, 3’UTR) cDNA 
was obtained from Addgene, generously deposited there by Dr. Michael Sutton and 
reported by Aakalu et al (Aakalu et al., 2001). DIV 17 neurons were transfected with 
EGFP (control) or dGFP- CaMKIIα-5’, 3’UTR cDNA alone. At DIV 21 transfected 
neurons were treated with DMSO or rapamycin (200 nM) for 100 min at 37°C. After 
treatment they were fixed with 4% paraformaldehyde for 20 min at room temperature. 
Neurons were immunostained and imaged as outlined under immunofluorescence. 
Putative HuD binding sites were removed by quick change mutagenesis using two 
complimentary oligos (sense strand: 5-CACTCACACCACTTCCTTCCACCA 
CTCTCTCCCTCTTCCTGGGTTTGGCTC-3; antisense strand: 5- 
CACTCACACCACTTCCTTCCACCACTCTCTCCCTCTTCCTGG GTTTGGCTC -3). 
The PCR protocol used to generate loopout was 95°C for 1 minute followed by 20 
cycles of 95°C for 30s, 50°C for 1 minute, and 68°C for 22 minutes. Nucleotides 
removed are highlighted in yellow in Figure S2.4C. 
 
Immunofluorescence and Image Analysis Immunofluorescence was performed as 
outlined in Raab-Graham et al., 2006. For staining of total protein, neurons were fixed 
with 4% paraformaldehyde, permeabilized with 0.25% Triton-X 100, and incubated with 
primary antibodies overnight at 4°C. Secondary antibodies conjugated to either Alexa-
488 (1:400, Invitrogen), Cy3 (1:500, Jackson labs), Alexa 647 (1:200, Invitrogen) or Cy5 
(1:200, Jackson labs) were used in appropriate combinations. For staining of surface 
expressed Kv1.1, fixed but non-permeabilized neurons were incubated overnight at 4°C 
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with Kv1.1 antibody (1:1000, Neuromab) that recognizes the extracellular epitope. 
Neurons were washed extensively with PBS for at least one hour to remove all excess 
antibodies before permeabilization. Z-stack images were acquired using a Leica SP5 
(Leica DM6000 CFS) confocal microscope (63X oil objective lens, N.A. 1.2) by 
sequential scanning. The Leica application suite advanced fluorescence (LAS AF) 
software was used for imaging acquisition. Dendrites were chosen blindly based on 
Kaede or EGFP signal that were at least 60 m in length. Signal intensity of puncta was 
determined by first tracing dendrites up to 150 µm on maximum projected images using 
the line scan tool in the LAS AF software package. Background was subtracted by 
determining the signal in a region close to the dendrite but void of all processes. Signal 
intensity for Kv1.1 puncta was defined as peaks that exceeded the mean signal intensity 
in control dendrites plus one standard deviation. 
 
Cell Body Analysis 
For analysis of cell bodies, a region of interest encompassing the cell body was drawn 
using ImageJ. The average intensity was measured for Kv1.1 and normalized to Kaede 
(Figure S2.1C), DsRed (Figure S2F), or EGFP (Figure S2.2E and Figure S2.4B). All 
integrated signal intensities were between the range of 0 and 255, to ensure that 
measurements were taken within the linear range. 
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RNA Affinity Capture of miRNAs Associating with Kv1.1 mRNA  
Kv1.1 FL, CR, or ΔmiR129 were PCR amplified using primers containing a T7 promoter 
and an extra connecting sequence of 20 nt. The PCR products were then purified and in 
vitro transcribed with T7 polymerase (Ambion) to generate RNA. The RNA fragments 
were then purified and hybridized with the synthesized Biotin-oligonucleotide (IDT) 
against the 20 nt tag, resulting in 5’ specific Biotin labeling of the RNA. 40 µg of cell 
extract from synaptoneurosomes (SN) or total neurons was then used to incubate with 4 
µg of Biotinylated RNA for 1 hour at room temperature (RT) in reaction buffer (10 mM 
HEPES, pH7.4, 150 mM NaCl, 3 mM MgCl2, 2.5% glycerol, 0.5% NP40, 0.2 mg/ml 
yeast t-RNA, protease inhibitor cocktail, 5 mM EDTA, RNase inhibitor 40 U/ml, 0.2 mM 
TCEP). The associated protein/RNA complex was pulled down with 10 µl of 
streptavidin-coated magnetic beads (Promega) by additional incubation of 1 hour at RT. 
The magnetic beads were then washed 3 times with reaction buffer and eluted with high 
salt buffer followed by heating at 95ºC for 5 min.  The eluent was subjected to miRNA 
detection using miRNA PCR system (Exiqon) with primers specific for miR-129 (Exiqon). 
Quantitative PCR for mRNA or miRNA  
Quantitative PCR was performed by using a SYBR Green PCR Master Mix as outlined 
by the manufacturer (Applied Biosystems) using a BioRad icycler. Fold changes were 
calculated as outlined by Raab-Graham et al. (2006). For steady state mRNA 
quantification (Figure 2.1B) primers against GAPDH were used as an internal 
housekeeping gene to control for variation between samples. For miRNA pull down 
(Figure 2.3), 10% total input RNA was used for internal control. All experiments were 
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performed in triplicate. Relative ratios were calculated by the equation: ratio= 
(2∆CPtarget(control-sample) ÷ 2∆CPreference(control-sample)), adapted from Pfaffle et al., 2001, where 
CP is the threshold cycle, the target is the transcript of interest, and the reference is 
GAPDH, 5S rRNA or 10% total RNA.  
 
Primers Used 
For cloning of MAP2-DTS: forward primer (5’ggcgcggccgcgatctagcactaaaatatcatttttc3’) 
and reverse primer (5’gcggtctagattactggaccttcttctttagttacc3’).  
For in vitro transcription of RNA for RNA affinity capture assay: Kv1.1 FL, forward 
primer (5’ ccaagcttctaatacgactcactatagggagaggccggacaacgtcaaggctatgacgg3’) and 
reverse primer (5’gttgggttttttttttctttttgcttgtttgg3’); mTRS, same forward primer as FL and 
reverse primer (5’ttaaacatcggtcaggagc3’).  
For 5’ specific biotinylation of mRNAs, Biotin labeled-5’agccttgacgttgtccggcc-3’ was 
used to hybridize with in vitro transcribed mRNAs.  
For detection of Kv1.1 mRNA pulled downed by HuD: Kv1.1 FL and ΔmiR-129, forward 
primer (5’ gccgccgcagctcctctactatcag3’) and reverse primer 
(5’gcttttgattgcttgcctggtgctt3’); Kv1.1 CR, forward primer (5’ggccatcctcagggtcatccgcttg3’) 
and reverse primer (5’acaccaccgcccaccagaaagcatc3’); CaMKIIα, forward primer (5’ 
cccttggatgttgctggaattctc3’) and reverse primer (5’ gggtgggtcaacactggagacaaac3’); GAP-
43 forward primer (5’ggaataaggatccgaggaggaaagg3’) and reverse primer 
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(5’cttaaagttcaggcatgttcttggt3’); GAPDH forward primer (5’gcaagagagaggccctcag3’) and 
reverse primer (5’tgtgagggagatgctcagtg3’);  
Homer1a forward primer (5’ tgggtgtctggagttcttcccttt 3’) and reverse primer (5’ 
atgaagacccatctgccacgatca 3’; adapted from Keene et al., 2008). 
 
LNA Transfection of Cultured Neurons 
g of 
EGFP DNA and 100 nM of LNA (either the scrambled or miR-129 specific probes from 
Exiqon) were used for transfection in a 1:5 dilution with Neurobasal medium. Neurons 
were incubated with the transfection mix for 2 hours at 37oC and returned to conditioned 
media afterwards. 24 hours post-transfection, neurons were fixed, permeabilized, and 
immunostained with Kv1.1 antibody as described in the immunofluorescence section. 
Signal quantitated by blindly choosing EGFP positive neurons. Fluorescent images of 
eGFP-transfected neurons and Kv1.1 signals were then taken as outlined in 
immunofluorescence section. 
 
miR-129 Overexpression Assay 
Cultured hippocampal neurons were transduced with control or miR-129-2 precursor 
lentivirus (3 X 105 IU; Biosettia) at DIV14. Neurons were treated at DIV21 for 75 min 
with DMSO or rapamycin. miR-129 overexpressing neurons were detected by 
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immunostaining for Dsred. Kv1.1 surface protein was detected by using an antibody that 
detects an extracellular domain of Kv1.1 (Neuromab) using nonpermeabilized neurons. 
 
Northern blot analysis 
4 micrograms of total RNA from DMSO or rapamycin treated cells or 2.5 micrograms of 
total RNA from scrambled or LNA transfected cells was separated on a Tris-borate-
EDTA-Urea-15% polyacrylamide gel. The gel was transferred onto a piece of 
Amersham Hybond N+ membrane (GE Healthcare, Illinois). The blot was UV-
crosslinked using the HL-200 HybriLinker (UVP, California). The blot was probed for 
hsa-miR-129 5p miRNA as previously described (citation below). The blot was stripped 
with boiling hot stripping buffer (0.1% sodium dodecyl sulfate [Sigma-Aldrich, Missouri] 
in double-distilled water), and then probed for hsa-let-7a. The sequences for the probes 
used were as follows: hsa-miR-129-5p, GCAAGCCCAGACCGCAAAAAG; hsa-let-7a-
5p, AACTATACAACCTACTACCTCA.  Quantitative values for the northern blot analysis 
were obtained using the Quantity One Analysis Software (Bio-Rad, California).  
(Grundhoff et al., 2006) 
 
Local Translation Assay 
Local Translation assay was carried out essentially as reported by Raab-Graham et 
al.(Raab-Graham et al., 2006) with the following modifications: primary culture of 
neurons (DIV 14 – 28) infected with Sindbis virus coding for Kaede-Kv1.1 FL or Kaede-
Kv1.1∆miR-129 for 18 to 24 hours were placed in 35mm dish containing HEPES based 
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aCSF with either DMSO or rapamycin (200 nM) and immediately imaged (before 
photoconversion). Confocal excitation imaging was accomplished using an upright 
microscope (Leica SP5) with a water immersion lens (HCX APO L20x/0.05W U-V-I) at 
room temperature. A 488 nm laser was used to excite Kaede-Kv1.1 and green emission 
was detected at 498 – 534 nm. Serial 1.0 μm z-sections of a neuron expressing Kaede-
Kv1.1 were acquired and then photo-converted using a DAPI filter for 30 seconds. After 
the initial photoconversion, the final image was acquired at 120 min post-
photoconversion. Maximum projected images from z-compressed stacks were used for 
data analysis using Leica SP5 software. For each neuron, the mean intensity of 8 -10 
puncta more than 60 μm from the soma was measured. All images were analyzed 
blindly using photoconverted protein as an unbiased selection of puncta. The magnitude 
of new protein synthesis was calculated by determining the fold increase of the mean 
green pixel intensity of puncta 120 min after photo-conversion (F) as compared to that 
immediately after photo-conversion (F0; time point 0) and calculated using the equation 
∆F/F=(F- F0)/ F0. Average basal translation under control conditions (Kaede-Kv1.1 FL, 
DMSO) was set equal to 100% and relative new translation measured with rapamycin or 
Kaede-Kv1.1∆miR-129 +/- rapamycin are reported as a percent increase over the 
average basal translation. 
 
In situ Hybridization of Kv1.1 mRNA in Cultured Neurons 
For in situ hybridization of infected neurons, cultures (DIV 21-28) were infected with 
Sindbis virus encoding either EGFP-Kv1.1 or EGFP as outlined previously (Raab-
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Graham et al., 2006). Briefly, 18 hours post infection, DIV21-28 neurons were fixed in 
4% paraformaldehyde, 4% sucrose for 18 minutes on ice. Neurons were washed 3X in 
PBS and 1X in SSC for 5 minutes. Neurons were permeabilized with 1% Triton-X 100, 
1X SSC for 30 minutes at room temperature followed by EGFP antisense (nt 5’- 
ATATAGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTCT-3’) DIG labeled oligo 
hybridization with an overnight incubation at 37oC. DIG labeled oligo was detected using 
a mouse anti-dig antibody (Roche) followed by an anti-mouse cy5 antibody (Jackson; 
www.singerlab.org).  
 
Transfection and Isolation of HEK293T cells  
HEK293T cells were transfected with Lipofectamine2000 as outlined by the 
manufacturer (Invitrogen).  48 hours post-transfection, cells were harvested by scraping 
the cells into buffer A (in mM; 150 NaCl, 10 HEPES [pH 7.4], 3 KCl, 2 CaCl2, 1 MgCl2, 
10 glucose, 250 sucrose, 5 TCEP) containing protease inhibitors (Complete, Roche) 
and phosphatase inhibitors (Sigma). Cells were lysed by homogenization. Lysates were 
centrifuged at 106 xg for 10 min at 4o C. Supernatant was transferred to a new tube and 
centrifuged for 17,000 xg for 20 min at 4o C. P2 pellet was resuspended in 100 µl of 
buffer A. SDS-sample buffer was added to a final concentration of 1X and samples were 
resolved on a 10% SDS-PAGE gel and transferred to nitrocellulose for western blot 
analysis. 
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HuD Pulldown of Kv1.1 mRNA from HEK Cells 
HEK293T cells were co-transfected with pCDNA3-myc-HuD and pCDNA3-Kaede-
Kv1.1-FL, CR, or ΔmiR-129. pCDNA3 alone and Kaede alone were used as controls. 
Cell lysates were harvested in polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM 
HEPES, 0.5% NP-40, TCEP 0.4 l/ml, RNaseOut 100 U/ml, 0.2% vanadyl 
ribonucleoside complexes, and EDTA free protease inhibitor tablet) followed by 
homogenization. After centrifugation at 14,000 xg, 4ºC, for 10 min, the supernatant was 
pre-cleared with 20 l/ml protein A/G beads (Santa Cruz) for 1 hr at 4ºC. Protein A/G 
beads (20 l/reaction) were coated with myc antibody (Sigma) (2 g/reaction) by 
incubating at RT for 2 hs in NT2 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 
0.05% NP-40, 15 mM EDTA, 8 U/ml RNaseOut, and 0.4 l/ml TCEP) supplemented 
with 5% BSA. The myc-antibody coated beads were then washed 6 times in NT2 buffer. 
Pre-cleared lysates were incubated with myc-antibody coated beads or beads alone in 
NT2 buffer supplemented with 3 l/ml RNaseOut at 4ºC overnight. After washing 6 
times with NT2 buffer, beads were treated with protease K (30 g/ml in NT2 buffer 
containing 0.1% SDS) at 55 ºC for 30 min and subjected to RNA extraction using TRI-
LS reagent (Molecular Research Center, Inc) following the manufacturer’s protocol. 
Purified RNAs were further treated with DNase (Ambion Turbo DNase kit) following the 
manufacturer’s protocol and used for reverse transcription (Superscript III kit from 
Invitrogen) with oligo dT primer. The reverse-transcribed cDNAs were then treated with 
RNase H (Invitrogen) for 30 min at 37 ºC and used for PCR with Kv1.1 specific primers 
(see primers used section).  
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HuD Overexpression in Cultured Neurons 
Cultured hippocampal neurons were transfected at DIV12 with cDNAs coding for myc-
tagged HuD or pCDNA3 with eGFP. 48 hours post-transfection neurons were treated 
with DMSO or cycloheximide (50 µM) for 4 hours, fixed and immunostained with Kv1.1 
or Kv4.2 specific antibodies (Neuromab). 
 
GST Pulldown 
Neurons were treated at DIV21 with 200 nM Rapa or DMSO for 75 min at 37 ºC in 
aCSF. Neuronal lysates were isolated in HB buffer and homogenized. Nuclei and 
unbroken cells were removed by low speed centrifugation (900 rpm, 10 min) and 
supernatant was transferred to a new tube containing TRI-LS reagent. RNA was 
isolated following manufacturer instructions (Molecular Research Center, Inc). 500 ng of 
GST or GST-HuD was incubated with 2.25 g RNA for 45 min at room temperature in 
binding buffer (20 mM HEPES, pH 7.9; 3 mM Magnesium acetate; 50 mM Potassium 
acetate; yeast tRNA (0.2 g/l), TCEP, RNaseOut and 5% glycerol). Protein agarose 
A/G beads (Santa cruz) were precoated with rabbit pan Hu antibody in binding buffer or 
rabbit-IgG (Santa cruz) in binding buffer without the yeast tRNA, TCEP, RNaseOut and 
glycerol for 2 hrs at room temperature. 50 l of the precoated IgG beads were used to 
preclear GST/RNA in solution for 1 hr at room temperature. IgG beads were removed 
by centrifugation and supernatant was added to precoated rabbit anti-HuD beads and 
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incubated for 2 hrs at room temperature. Beads were washed with diluted binding buffer 
(0.5X) without glycerol 6 times and then eluted with TRI reagent following 
manufacturer’s protocol (Zymogen, the Direct-zol RNA minikit). Isolated RNA was 
treated with Dnase I (Ambion Turbo DNase kit) and reverse transcribed using the iScript 
cDNA Synthesis kit (Bio-Rad) following manufacturer’s protocol. cDNA was treated with 
RNase H and subjected to PCR using Kv1.1, GAP43 and CaMKIIα specific primers (see 
primers used section). PCR was done using the iQ SYBR green kit (Biorad). PCR was 
terminated between cycle 25-30 to prevent saturation.  
mRNA Degradation Assay 
mRNA degradation assay was carried out essentially as previously described (Origanti 
et al., 2012). In brief, DIV 21 cultured cortical neurons were treated with actinomycin 
(12M) for 4 hrs prior to the addition of rapamycin (200 nM). Neurons were treated with 
rapamycin or DMSO plus actinomycin for 75 min in HEPES-based ACSF at 37 ºC. 
Neurons were harvested in HB buffer containing TCEP and RNaseOut and 
homogenized. Following a low speed centrifugation (900 rpm, 10 min), the supernatant 
was removed to a new tube containing TRI-LS. RNA was isolated following 
manufacturer instructions (ABI). Total RNA was treated with DNAse, quantitated, and 
subjected to quantitative RT-PCR using CaMKIIα specific primers as outlined under 
quantitative PCR section. Degradation was measured as a percent remaining after 
treatment with rapamycin as compared to DMSO treated neurons.  
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 Chapter 3: Dynamic changes in the RNA-binding factor miR-129-
5p result in resetting the action potential threshold in CA1 
pyramidal neurons by Kv1.1 in Temporal Lobe Epilepsy 
 
Introduction 
 
Neuronal insult or injury is often followed by changes in intracellular signaling 
that, in some cases, can lead to a persistent state of neuronal hyperexcitablity such as 
temporal lobe epilepsy (TLE). The serine/threonine kinase mTOR is overactive following 
status epilepicus (SE) in models of TLE (Brewster et al., 2013; Zeng et al., 2009). 
mTOR is best characterized for its role in promoting translation of mRNAs. Therefore, it 
is often hypothesized that overactive mTOR in neurological disorders results in 
excessive protein synthesis (Hoeffer and Klann, 2010). However, a number of studies 
suggest that there is a reduction or loss of protein expression with respect to voltage-
gated ion channels (Poolos and Johnston, 2012). Our previous work established a link 
between mTOR activity and the dendritic expression of the delayed rectifier potassium 
channel Kv1.1. Findings from that study showed that activation of mTOR represses the 
local protein synthesis of Kv1.1 in neuronal dendrites (Raab-Graham et al., 2006). 
Remarkably, increased seizure susceptibility directly correlates with a decrease in Kv1.1 
gene expression (Rho et al., 1999; Robbins and Tempel, 2012; Smart et al., 1998). 
Likewise, overexpression of Kv1.1 has been shown to eliminate seizures in a rat model 
of epilepsy (Wykes et al., 2012). 
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Identifying mechanisms through which mTOR activity represses the translation of 
ion channel mRNA may be important for understanding the causative nature of 
epilepsy. RNA-binding proteins and microRNAs can bind to the same target mRNAs 
and antagonize each other’s function (Meisner and Filipowicz, 2011). Recent work from 
our laboratory determined the microRNA, miR-129-5p and the RNA binding protein HuD 
display this exact relationship with respect to KV1.1 translation (Sosanya et al., 2013). 
mTOR-dependent repression of Kv1.1 mRNA translation is mediated by binding of miR-
129-5p while under conditions where mTOR activity is reduced, miR-129-5p binding is 
relieved and HuD restores translation (Sosanya et al., 2013). These findings have led 
us to ask the questions (1) is Kv1.1 protein reduced in epilepsy when mTOR is 
overactive, (2) what is the physiological consequence of changes in Kv1.1 protein 
expression, and (3) are the RNA-binding factors that regulate Kv1.1 mRNA translation 
aberrantly expressed in epilepsy? 
Herein we report that Kv1.1 protein dynamically changes over the course of 
several days following status epilepticus, a critical period during which neuronal 
remodeling occurs that contributes to chronic epilepsy. Interestingly, Kv1.1 expression 
sharply increases 5 days post status epilepticus (post-SE) peaking at 14 days post-SE 
followed by a dramatic decrease at 15 days post-SE which is significantly different from 
control by 21-30 days post-SE, a time point associated with the onset of behavioral 
seizures (Mascott et al., 1994) and where we observe significant increase in the number 
of behavioral seizures. Consistent with the changes in Kv1.1 protein, the threshold for 
action potential firing is lower by 21-30 days compared to control. This overall decrease 
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in Kv1.1 expression 21-30 d post-SE corresponds to an increase in mTOR activity and a 
significant increase in miR-129-5p. Collectively, these data suggest that mTOR/miR-
129-5p-mediated repression of Kv1.1 translation contributes to the neuronal 
hyperexcitability observed in epilepsy. 
 
Methods 
Animals. Status epilepticus (SE) was induced in 8-week old male Sprague-Dawley rats 
by intraperitoneal injection of kainic acid (10 mg/kg). The behavior of the animals was 
observed, and seizures were scored according to the Racine scale (Racine, 1972). One 
hour after the onset of SE (Class V on the Racine scale), seizures were terminated by 
subcutaneous injection of sodium pentobarbital (PB; 30 mg/kg). All animal experiments 
were performed in accordance with guidelines approved by the Institutional Animal Care 
and Use Committee (IACUC) at The University of Texas-Austin.  
Continuous Video Monitoring. KA rats (n=3) were video monitored from d2 to d30 post-
SE. Videos were watched and scored by a 3rd party over an 8 hour period. Only 
behavioral seizures ranging from Class III to Class V on the Racine scale were counted. 
Slice Preparation. Animals were anesthetized using a lethal dose of ketamine and 
xylazine. Once deeply anesthetized, animals were perfused intracardially with ice-cold 
modified ACSF containing (in mM) 210 sucrose, 2.5 KCl, 1.2 NaH2PO4, 25 NaHCO3, 
0.5 CaCl2, 7.0 MgCl2, and 7.0 dextrose bubbled with 95%O2 / 5%CO2. The brain was 
removed and bisected along the midline. One hemisphere was used for slice 
preparation for electrophysiological recording and the other hemisphere was used for 
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biochemical analyses (see below). The hemisphere was mounted and 350 µm thick 
slices were made using a microtome (Vibratome, St. Louis MO). Slices were placed in a 
holding chamber filled with ACSF containing (mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 
25 NaHCO3, 2 CaCl2, 2 MgCl2, and 12.5 dextrose warmed to 35 C for 20 min and then 
placed at room temperature for < 6 hrs until needed for recording. 
Electrophysiology. Slices were placed individually as needed into a submerged 
recording chamber continuously perfused with control extracellular saline (see below). 
Slices were viewed with a Zeiss Axioskop using infrared video microscopy and 
differential interference contrast (DIC) optics. For all recordings, the ACSF solution 
contained (mM): 125 NaCl, 3 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1 MgCl2, and 
12.5 dextrose and was bubbled continuously with 95%O2 / 5% CO2 at 31-33oC. Fast 
glutamatergic and GABAergic synaptic transmission was blocked by a combination of 
20 µM DNQX, 50 µM AP5, 2 µM gabazine, and 5 µM CGP55845.  
Patch pipettes were pulled from borosilicate glass and had a resistance of 4-8 
M when filled with the internal recording solution containing (in mM): 120 potassium 
gluconate, 20 KCl, 10 HEPES, 4 NaCl, 4 MgATP, 0.3 Na-GTP and 7 phosphocreatine 
(pH 7.3 with KOH). Whole cell recordings were made from the soma of CA1 pyramidal 
neurons using a Multiclamp 700A or Dagan BVC in current clamp mode. Series 
resistance was monitored throughout the recording, and experiments in which the series 
resistance exceeded 30 MΩ were discarded. 
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Data Acquisition and Analysis. Data were sampled at 40 kHz, filtered at 5 kHz and 
digitized by an ITC-18 interface connected to computer running Axograph X. Data 
analyses were performed with Axograph X. 
Western blot analysis. Synaptoneurosomal (SN) protein and RNA was harvested from 
the hippocampus as outlined by Sosanya et al. (2013). Proteins were separated by 
SDS-PAGE, transferred to nitrocellulose, and blocked with 5% milk+Tween 20. Blots 
were then probed with antibodies against Kv1.1 (1:500; neuromab), p-mTOR (1:500, 
Cell Signaling), mTOR (1:500, Invitrogen), HuD (1:500; Millipore), and Tubulin (1:2000). 
Alexa680 or Alexa800 (1:2000; invitrogen) were used as secondary antibodies and 
imaged on the Leica Odyssey. 
Immunohistochemistry. Control and KA injected rats were perfused with ice cold PBS 
and post fixed with 4% formaldehyde overnight at 4oC. 80 µm thick coronal sections of 
the hippocampus were taken on a vibratome and placed in PBS. Hippocampal slices 
with similar morphology were double stained for Kv1.1 and tubulin. Slices were blocked 
overnight at 4oC in blocking solution (10% goat serum with 0.3% Triton X-100 in PBS). 
and then incubated in primary antibody (m anti- Kv1.1 (1:200, neuromab) and rb anti 
tubulin (1:200)) overnight at RT in blocking solution. The following day, slices were 
washed in PBS for 1x10min, 1x30min, and 1x40 min and then incubated in blocking 
solution for 2 hr at RT. Slices were then incubated overnight in secondary antibody 
followed by same washing protocol as above. Once mounted on glass slides slices 
were imaged on a Leica microscope using a 20x objective.  
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Reverse Transcription-quantitative PCR (RT-PCR). SN RNA was isolated using 
Zymogen Direct-zol RNA miniprep kit according to the manufacturer’s directions. RT-
PCR for miR-129-5p or 5S rRNA was done using the miRCURY LNA Universal RT 
microRNA PCR kits (Exiqon; universal cDNA #203300 and Sybr green master mix 
#203450) using miR-129 specific primers (Exiqon) according to the manufacturer’s 
directions. Fold changes were calculated as outlined by Raab-Graham et al. (2006) and 
Sosanya et al. (2013). Relative ratios were calculated by the model as previously 
described (Pfaffl, 2001) and calculated by the equation: ratio= (2∆CPtarget(control-
sample) ÷ 2∆CPreference(control-sample)), where CP is the threshold cycle, the target 
is the transcript of interest, and the reference is 5S rRNA. 
Statistical Analyses. All data are expressed as mean ± S.E.M. Statistical comparisons 
were made using one-way or two-way ANOVA followed by Tukey-Kramer or Dunnett’s 
multiple comparisons post-hoc test or Student’s t-test (paired or unpaired as 
appropriate) with Prism software (GraphPad). Linear fits and correlations were made 
using Prism. Data were considered statistically significant if p < 0.05. 
 
Results 
 
Number of Behavioral Seizures peak at 21 days post-SE when compared to earlier 
time points. 
The kanic acid (KA) model of TLE has been useful for identifying molecular 
changes that occur during epileptogenesis leading to the progression of spontaneous 
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recurrent behavioral seizures. To determine the time course for the development of 
seizure activity KA injected rats were continuously video monitored and behavioral 
seizures ranging from Class III-V (Racine, 1972) were scored from 2 to 21 days post-
SE. Interestingly, seizure number was depressed at day 14 post-SE and then gradually 
increased from day 15 to day 21 where seizure number became significantly higher 
when compared to all other time points (Figure 3.1).  
   
Increased mTOR activity corresponds to peak number of behavioral seizures. 
Previously, it was reported that mTOR was overactive in the kainic acid model of 
TLE (Zeng et al., 2009). In light of the behavioral progression data (Figure 3.1) we set 
out to determine the time course of mTOR activity post-SE. To address this question, 
we examined mTOR activity in the hippocampus of control rats (0d, no KA) and rats 2, 
5, 14, 15, and 21-30 days post-SE. Synaptoneurosomes isolated from hippocampi were 
subjected to Western blot analysis for phospho-mTOR (pmTOR) and total mTOR. The 
ratio of pmTOR/mTOR served as a readout for mTOR activity. Notably, mTOR activity 
was significantly depressed 14d post-SE followed by a sharp increase at 15d post-SE 
which was significantly different from control by 21-30d post-SE (control: 1.00±0.02, 2d 
post-SE: 1.03±0.05, 5d post-SE: 1.03±0.04; 14d post-SE: 0.56±0.25, 15d post-SE: 
1.22±0.19, 21-30d post-SE: 1.25±0.11; Figure 3.2A). This significant increase in mTOR 
activity corresponds to the significantly higher number of seizures 21 days post-SE. As 
a further control, we measured mTOR activity in KA injected rats that did not progress 
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past Class III on the Racine scale and observed no change in mTOR activity when 
compared to control (Figure 3.2B) 
 
Bidirectional changes in Kv1.1 expression in TLE. 
Shortly after periods of intense activity neurons may undergo changes in ion 
channel function and/or expression that can reduce the overall activity of the neuron 
(Fan et al., 2005; Narayanan and Johnston, 2010; Shin et al., 2008). However following 
status epilepticus, these changes are often transient, resulting in persistent states of 
neuronal hyperexcitability and ultimately leading to the onset of recurrent seizure activity 
(Sun et al., 2013). The overexpression of Kv1.1 can provide protection against seizures 
in drug resistant focal neocortical epilepsy (Wykes et al., 2012). We therefore asked if 
Kv1.1 expression undergoes changes following kainic acid induced status epilepticus 
(SE): higher expression in the short-term, to dampen neuronal excitability, followed by a 
reduction of expression that contributes to a state of hyperexcitability. To test our 
prediction, we measured Kv1.1 expression at distinct time periods (0, 2, 5, 14 and 15 
days after KA injection) and then again at late post-SE (21 – 30 days after KA injection) 
when behavioral seizures are significantly different from all other time points. As 
predicted, in Western blot analysis of isolated hippocampal synaptoneurosomes there 
was an increase in Kv1.1 expression of ~27% by 5 days post-SE and of ~71% by 14 
days post-SE (0d no-SE: 1.00±0.04, 2d post-SE: 1.07±0.08, 5d post-SE: 1.27±0.09; 14d 
post-SE: 1.71±0.25; 15d post-SE: 0.98±0.05; Figure 3.3A). In contrast, 21-30d post SE, 
resulted in reduced Kv1.1 levels by ~50% relative to control (21-30d post-SE: 
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0.54±0.15; Figure 3.3A). As a further control, we observed no change in Kv1.1 
expression between control and KA injected rats that did not reach SE (Figure 3.3B).  
These results suggest that the potential neuroprotective increase in Kv1.1 expression 
early after SE fails to be sustained at later stages of TLE and may contribute to the 
gradual increase in behavioral seizures from day 15 to day 21 post-SE as mTOR 
activity increases. 
 
Bidirectional changes in Kv1.1 expression post-SE in the hippocampus.  
To determine the regional distribution of changes in Kv1.1 expression post-SE 
we perfused and sectioned the hippocampus from control, 14d, and 21-30d post-SE 
animals. Slices within the same region of the hippocampus were immunostained for 
Kv1.1 and Tubulin. Consistent with our western blot results, we observed an increase in 
Kv1.1 protein expression both in the CA1 and CA3 regions 14 d post-SE when 
compared to control (Figure 3.4A), with a significant decrease by 30days post-SE 
relative to control animals (Figure 3.4B). 
 
Dynamic changes in Kv1.1 expression post-SE alter the threshold for action 
potential firing.  
In cortical neurons, dynamic changes in Kv1 channels reset the threshold for 
action potential firing (Vth) (Higgs and Spain, 2011). Thus, one possible functional 
consequence of the changes in KV1.1 expression post-SE would be to alter Vth in 
hippocampal pyramidal neurons. To test if Vth is altered, we recorded single action 
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potentials elicited in CA1 pyramidal neurons from KA and saline injected rats. The 
amplitude of a 100-msec current pulse was adjusted so that a single action potential 
occurred in the middle (~ 50 msec latency) of the current injection.  
 Since behavioral seizures in KA-treated rats are significantly higher starting at 
21 days post-SE compared to control animals (Figure 3.1), we measured the 
contribution of Kv1.1 to the threshold of action potential firing at this time point. 
Consistent with our Western blot analysis, we found that Vth with 100ms current 
injections in 21-30d post-SE CA1 pyramidal neurons was hyperpolarized by ~3 mV 
compared to control neurons (Figure 3.5A and B). Moreover, blocking Kv1-containing 
channels with 4-AP (50 µM) significantly hyperpolarized Vth in control neurons (Figure 
3.5A, B, and D). Consistent with a reduction in Kv1.1 protein expression, there was 
however, no significant effect of 4-AP on the Vth with the 100ms current injections in KA 
neurons (Figure 3.5A, B and D). The Vth of action potentials elicited with 2-msec current 
injections was not significantly different between control and 21-30d post SE animals 
and was insensitive to 4-AP (Figure 3.5C and D). These data support the hypothesis 
that Kv1.1 expression is reduced 21-30 days post-SE and that this loss of Kv1.1 
contributes to CA1 pyramidal hyperexcitability by reducing the threshold for action 
potential firing. 
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miR-129-5p, a negative Kv1.1 regulator, levels are heightened when Kv1.1 is 
reduced. 
What is the molecular mechanism accounting for reduced Kv1.1 expression in 
TLE? Recently, our laboratory determined that the microRNA, miR-129-5p negatively 
regulates the expression of Kv1.1 in neurons when mTOR is active and that the RNA-
binding protein HuD positively regulates the translation of Kv1.1 mRNA when mTOR is 
inhibited (Sosanya et al., 2013). To determine if changes in the dynamic relationship 
between miR-129-5p, HuD, and Kv1.1 is altered post-SE, we determined the expression 
levels of HuD and miR-129-5p 21-30d post-SE. Based on our model, for Kv1.1 
expression to decrease 21-30d post-SE either miR-129-5p levels will increase or HuD 
levels will be reduced. Figure 3.6A shows that miR-129-5p levels increase by ~70% 21-
30d post-SE corresponding to reduced Kv1.1 levels (Figure 3.6A; control: 1.00±0.06, 
21-30d post-SE: 1.76±0.33) and HuD levels remain constant (Figure 3.6B, control: 
1.00±0.21, 21-30d post-SE: 0.95±0.30). Together this data suggests that increased 
levels of miR-129-5p in TLE favor translational repression of Kv1.1 mRNA resulting in 
reduced protein levels and a lower Vth for firing an action potential. 
Discussion 
Many ion channels are dynamically regulated during epileptogenesis (Poolos and 
Johnston, 2012) and a growing number are being linked to changes in mTOR activity 
(Brewster et al., 2013; Lee et al., 2011). We recently described a mechanism by which 
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mTOR can influence the expression of the delayed rectifier potassium channel Kv1.1 by 
regulating two RNA-binding factors, HuD and miR-129-5p, that promote and repress 
KV1.1 mRNA translation, respectively (Sosanya et al., 2013). In this study, we found 
that hippocampal expression of Kv1.1 is higher 5 to 14 days post-SE. This increase in 
Kv1.1 expression is likely due to the low levels of mTOR activity, a condition that favors 
the release of miR-129 repression (Figure 3.7, left panel). In contrast, when miR-129-5p 
levels are heightened 21-30 days post-SE possibly shifting the balance toward Kv1.1 
mRNA repression thus leading to lower expression of Kv1.1 and a significant 
hyperpolarization of CA1 pyramidal neuron action potential threshold (Figure 3.7, right 
panel, Late TLE, red arrow). This may contribute to hippocampal pyramidal neuron 
hyperexcitability during a time when recurrent spontaneous seizures occur (Figure 3.1). 
Our findings propose a mechanistic model explaining the posttranscriptional regulation 
of an ion channel by mTOR activity in a model of TLE (Figure 3.7). 
Interestingly, in a different model of epilepsy, Brewster et al., demonstrated that 
while there is a trend toward a decrease in Kv1.1 protein two weeks post status 
epilepticus, the chronic use of the mTORC1 inhibitor rapamycin did not reverse interictal 
epileptiform activity or increase the levels of Kv1.1 in the hippocampus of epileptic rats 
(Brewster et al., 2013). Collectively, our results suggest that to effectively increase 
Kv1.1protein in TLE, miR-129-5p levels need to be reduced and HuD levels need to 
increase. Consistent with this idea, HuD protein has been shown to decrease with acute 
treatment of rapamycin (Sosanya et al., 2013). Perhaps chronic use of rapamycin 
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reduces HuD protein to dangerously low levels, further decreasing the probability for it 
to bind to Kv1.1 mRNA. 
The initial rise in ion channel expression in TLE, reported in this study for Kv1.1 
and previously seen with HCN channels (Shin et al., 2008), may help explain the 
reduced numbers of behavioral seizures during the early stages or latent period. 
Moreover, the failure to sustain elevated levels of these channels may lead to chronic 
epilepsy. The concurrent increase in mTOR activity coincides with the decline in 
channel expression. Why mTOR activity fails to renormalize in TLE is an open question. 
Interestingly, a recent report suggests that mTOR activity also inhibits the expression of 
the homeostasis protein polo-like kinase 2 (PLK2) in a neonatal seizure model (Sun et 
al., 2013). Although the mechanism of repression has not been established, it has been 
shown that PLK2 down regulates mTOR signaling through its interaction with the 
upstream inhibitor tuberous sclerosis complex 1 (Matthew et al., 2009). Collectively, 
these studies suggest that mRNAs that are repressed by mTOR activity may be good 
antiepileptic targets. 
In summary, activity dependent mRNA translation through the competition of 
RNA binding factors for their target mRNAs suggests that altered levels of these factors 
can shift the balance toward repression or translation and lead to disease. The present 
study shows that elevated expression of miR-129-5p that is not properly counter 
balanced by HuD may lead to the reduced Kv1.1 expression and a depolarized action 
potential threshold resulting in neuronal hyperexcitability. Although Kv1.1 mRNA is not 
the only mRNA translationally regulated by miR-129-5p and HuD, its function is not 
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compensated by other potassium channel since deletion or loss of function mutations of 
the kv1.1 gene causes epilepsy in mice (D'Adamo et al., 2013). These studies provide a 
unique model of regulating ion channel expression which may be relevant to other 
mTOR related diseases associated with epilepsy, such as Tuber Sclerosis Complex, 
Fragile X syndrome, and Alzheimer’s disease (Ma et al., 2010; Narayanan et al., 2007; 
Pei and Hugon, 2008; Sharma et al., 2010; Spilman et al., 2010; Zeng et al., 2011). 
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Chapter 4: The RNA-binding protein HuD mediates CaMKIIα 
Branch - specific expression 
Introduction 
mTOR is a protein kinase whose activity is required for late-LTP (L-LTP) and 
memory consolidation. mTOR consists of two subunits TORC1 and TORC2. mTORC1 
is a serine/threonine kinase that promotes cap-dependent translation by 
phosphorylating p70 S6 kinase (S6K) and elF4E binding protein (4E-BP). In neurons, 
mTOR kinase is activated by the Ca2+- dependent activation of PI3Kinase and has been 
found to be active in dendrites (Hoeffer and Klann, 2009; Tang et al., 2002). 
One notable plasticity related protein whose mRNA translation is regulated by 
mTORC1 is Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) (Gong et al., 
2006; Sosanya et al., 2013). Several studies have verified the importance of CaMKIIα 
both in the induction phase and maintenance (late) phase of LTP and memory (Mayford 
et al, 1996; Miller et al., 2002). The importance of locally translated CaMKIIα mRNA to 
memory consolidation was demonstrated in a mouse where the dendritic targeting 
sequence of CaMKIIα in the genome was disrupted (Miller et al., 2002). Moreover, 
recent data demonstrates that synapses undergoing protein synthesis- LTP tend to 
occur within the same dendritic branch (Govindarajan et al., 2010). Thus, further insight 
into the subcellular loci of CaMKIIα mRNA translation in dendrites may yield information 
regarding the importance of dendritic branches in memory formation. 
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HuD is an RNA-binding protein whose expression has been correlated with both 
spatial learning and contextual fear conditioning (Bolognani et al., 2006). 
Overexpression of several targets of HuD are associated with improved cognition. 
Moreover, HuD has gained recent attention for its ability to relieve microRNA repression 
(Kundu et al., 2012; Sosanya et al., 2013). Collectively, these data strongly support a 
role for HuD to relieve mRNA repression and promote the translation of mRNAs that 
support learning and memory.  
Recently, we determined that mTORC1 kinase serves as a switch for translation 
of specific mRNAs through the RBP HuD. When mTORC1 is active HuD binds to its 
high affinity target mRNAs, one of them being CaMKIIα mRNA, stabilizing the mRNA 
and promoting its translation. When mTORC1 is inhibited CaMKIIα mRNA degrades, 
thus releasing HuD allowing it to bind to low affinity target mRNAs, such as the voltage-
gated potassium channel Kv1.1. Whether HuD unbinds CaMKIIα mRNA prior to 
degradation and how the mRNA is degraded is unclear. 
A great deal is known about global mTORC1 regulation of translation; however, 
little is known about how mTORC1 may regulate translation in a site-specific manner. 
Based on our previous work the RNA binding protein HuD appears limited and 
determines which mRNAs are translated based on affinity in an mTORC1-dependent 
manner (Sosanya et al., 2013). Herein, we demonstrate the unexpected role for HuD in 
mTORC1 regulated mRNA translation of CaMKIIα in a branch specific manner. We 
have previously demonstrated that both CaMKIIα mRNA and protein expression 
decrease when mTOR is inhibited (Sosanya et al., 2013). Using immunocytochemistry 
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to map CaMKIIα protein, we determined that HuD increases the expression of CaMKIIα 
by protecting it from degradation via HuD differential branch targeting.  Thus, HuD 
differential branch expression may affect the propensity of a dendritic branch to undergo 
site-specific and long-lasting forms of plasticity. 
Experimental Procedures 
Transfection and Immunocytochemistry 
Neurons were cultured as previously described in Sosanya et al., 2013. Cultured 
hippocampal neurons were transfected with pCDNA+eGFP or  HuD+eGFP at DIV 17-20 
using Lipofectamine2000 (Invitrogen). At DIV 21-24, neurons were treated with 200 nM 
Rapamycin or DMSO (vehicle) for 75 min. Following treatment, neurons were fixed for 
20 min at RT in 4% paraformaldehyde followed by 3 washes in 1X PBS. Neurons were 
then permeabilized for 5 min with 0.25% triton and blocked for 1 hour in Blocking 
Solution (8% Goat serum, 0.25% Triton, 1X PBS). Primary antibody was incubated ON 
at 4oC and Secondary antibody was incubated for 1 hour at RT in Blocking Solution. 3- 
10 min washes in 1X PBS were performed after each antibody incubation. Coverslips 
were mounted with Flourmount and imaged the following day using the Leica Confocal 
Microscope 63x objective. 
Antibodies 
Primary antibodies used for immunostaining include mouse anti-CaMKIIα (1:200, 
Lifespan), chicken anti-GFP (1:200, Aves), mouse anti-Kv1.1 extracellular (Neuromab, 
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1:200), rabbit anti-myc (1:200). Secondary antibodies used for immunostaining are 
Alexa488 anti-GFP (1:400), Alexa555 anti-mouse (1:400), and Alexa647 anti-rabbit 
(1:400). 
PAT Assay 
PAT assay was carried out according to Wu et al. and similar to Udagawa et al. (8,9). 
Cultured cortical neurons between DIV21-28 were treated in aCSF for 10 min for time 
point 0 or Rapamycin for 60, 90, or 180 min. Neurons were harvested in HB buffer B (20 
mM HEPES, pH 7.4, 5 mM EDTA, pH 8.0, with RNaseOut and TCEP) and 
homogenized. Following a low-speed spin (900rpm, 10min) total RNA was isolated 
using Tri-LS following the manufacturer protocol (ABI). Reverse transcription was 
performed with the anchor-oligo dT primer (5’ GCGAGCTCCGCGGCCGCGT(12)) using 
superscript III first strand cDNA synthesis kit (Invitrogen). Subsequent PCR with 100ng 
of cDNA using Amplitaq Gold (ABI) with specific CaMKIIα forward 
(5’CCGAAGCTTCTCTCTCTTTCTTTTTTATTATGTGGCTGTG; oligo#1) and reverse 
(5’ GCTCTAGACACATAAATTTGTAGCTATTTATTCC) primers were used (Wu et al., 
1998). To detect the poly(A) tail oligo#1 was used in combination with the anchor-oligo 
dT primer. PCR was done with an initial denaturation step (95oC, 5min) followed by 10 
cycles of (15 sec at 95oC, 15 sec at 45oC, 1min at 72oC) and then 50 cycles of (15 sec 
at 95oC, 15 sec at 58oC, 1min at 72oC) and finally 7 min at 72oC. The PCR products 
were resolved in a 2% agarose gel. As a control for the PAT assay, 600 ng of total RNA 
was treated with RNase H and oligo dT for 20 min at 37 oC prior to RT-PCR. 
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Results 
mTORC1 regulates the expression of CaMKIIα in a branch specific manner 
N-methyl-D-aspartate receptor (NMDAR) activity is necessary for many forms of 
plasticity. We have previously demonstrated that in cultured hippocampal and cortical 
neurons (21 – 28 days in culture), mTORC1 kinase is phosphorylated and thus active 
through NMDAR stimulation ( Raab-Graham et al., 2006; Sosanya et al., 2013). Acute 
treatment with rapamycin reduces mTORC1 kinase activity (Raab-Graham et al., 2013).  
Neuronal activity stimulates the mTOR-dependent local protein synthesis of 
CaMKIIα mRNA (Gong et al., 2006;  Miller et al., 2002; Tang et al., 200); however, 
whether mTOR regulated translation of CaMKIIα mRNA occurs in one daughter branch 
over the other is unknown.  To determine if mTORC1 activity regulates CaMKIIα 
expression in a branch specific manner we treated eGFP expressing neurons with the 
carrier or the mTORC1 inhibitor rapamycin for 75 minutes and stained for CaMKIIα 
protein with a specific antibody. eGFP allowed us to clearly visualize individual neurons 
and quantitate branch-specific expression changes using the eGFP signal as a way to 
normalize for individual dendritic volume between branches. We first confirmed that 
mTOR activity increases the expression level of CaMKIIα in dendrites by measuring the 
CaMKIIα signal in the primary apical dendrite prior to the first branch point. As 
previously, observed inhibition of mTOR with rapamycin reduced the dendritic 
expression of CamKIIα to ~ 49% ± 0.05 (Figure 4.1A and B). Next, we measured the 
average signal intensity of CaMKIIα in each daughter branch within 5µm of the branch 
point normalized by eGFP. Again, mTOR activity increases the overall expression of 
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CaMKIIα in the secondary branches (Figure 4.1B). As a control we measured Kv1.1 
dendritic protein expression following mTORC1 inhibition. As previously observed 
inhibition of mTOR with rapamycin increased the dendritic expression of Kv1.1 (Figure 
4.1C; Primary branch: Control: 1.00±0.17; Rapa: 2.00±0.45; Daughter branch: Control: 
1.00±0.13; Rapa: 1.72±0.27). To determine the branch specific expression of CaMKIIα 
we developed a branch variability index where we took the absolute value of the 
normalized CaMKIIα signal in daughter branch A – daughter branch B. A value above 
zero suggests that more protein is expressed in one branch over the other. Indeed, 
CaMKIIα protein favors one branch over the other by ~55 ± 15% in neurons where 
mTOR is active relative neurons treated with the mTOR inhibitor rapamycin (Figure 
4.1D; Control: 1.00±0.15; Rapa: 0.45±0.07). However, Kv1.1 branch variability remains 
constant with mTORC1 inhibition (Figure 4.1D). 
mTOR inhibition causes the rapid degradation of CaMKIIα mRNA by the removal 
of its poly(A) tail. 
How does mTOR inhibition reduce the branch specific expression of CaMKIIα? 
We recently demonstrated that the mTOR-dependent expression of CaMKIIα relies on 
its mRNA binding to the RNA-stabilizing protein HuD. Notably, when mTOR activity is 
inhibited with rapamycin high affinity HuD target mRNAs such as CaMKIIα protein is 
significantly reduced and its mRNA rapidly degrades. HuD is known to stabilize its 
target mRNAs by delaying the onset of mRNA degradation, a process that depends on 
the length of the poly(A) tail (Beckel et al., 2002). Furthermore, in yeast, it has been 
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reported that inhibition of TORC1 kinase accelerates the deadenylation-decapping 
pathway (Albig and Decker, 2001). mRNAs that decay rapidly in the presence of 
rapamycin have shorter poly(A) tails possibly through rapid deadenylation (Albig and 
Decker, 2001). In light of these data, we predict that overexpression of HuD may restore 
CaMKIIα branch variability index back to levels when mTOR is active by preventing its 
mRNA degradation with rapamycin in one branch over the other.  To address this 
question we first assessed if mTOR activity promotes the degradation of CaMKIIα 
mRNA degradation by shortening its poly(A) tail. We analyzed the length of the poly(A) 
tail of CaMKIIα mRNA when mTORC1 kinase was active and/or inhibited by rapamycin. 
As shown in Figure 4.1E, the poly(A) tail of CaMKIIα mRNA is indeed shorter in neurons 
treated with rapamycin and is sensitive to RNase H treatment (Figure 4.1F), supporting 
the idea that CaMKIIα mRNA degrades when mTORC1 kinase is inhibited. As a further 
control, we measured the poly(A) tail length of Kv1.1. Consistent with the idea that 
mTOR inhibition reduces the branch specific expression of CaMKIIα through mRNA 
degradation, Kv1.1 mRNA levels and the length of its poly(A) tail remain the same 
regardless of mTOR activity (Figure 4.1G; Sosanya et al., 2013). 
The RNA-binding protein HuD rescues CaMKIIα protein expression and branch 
variability when mTOR is inhibited. 
Next we asked if overexpression of HuD can restore the CaMKIIα BVI when 
mTOR is inhibited by rapamycin by stabilizing CaMKIIα mRNA as indicated by an 
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increase in protein levels (Sosanya et al., 2013). Indeed, CaMKIIα protein expression 
increased significantly in the HuD overexpressing primary dendrite both when mTOR is 
active and inhibited with rapamycin (Figure 4.2A and B; HuD DMSO: 1.12±0.13; HuD 
Rapa: 1.52±0.23). Furthermore, the levels of CaMKIIα in the HuD overexpressing 
secondary branches were relative to control levels with rapamycin (Figure 4.2C). 
Interestingly, overexpression of HuD did not further increase the branch variability index 
for CaMKIIα when mTOR is active; however, it did restore it back to control levels when 
mTOR is inhibited with rapamycin (Figure 4.2D; HuD DMSO: 0.97±0.12; HuD Rapa: 
0.82±0.13). These results suggest that HuD stabilizes the expression of CaMKIIα 
mRNAs in one daughter-branch over the other. 
myc-HuD targets one branch over the other resulting in its differential branch 
expression 
How does HuD rescue CaMKIIα differential branch expression when mTORC1 is 
inhibitied? To address this question, we measured overexpressed myc tagged HuD 
(myc-HuD) levels following mTORC1 inhibition in both primary and daughter branches. 
myc-HuD levels do not change with mTORC1 inhibition in either primary or daughter 
branches (Figure 4.2E, F and G; Primary: HuD DMSO: 1.00±0.11, HuD Rapa: 
1.01±0.11; Daughter branch: HuD DMSO: 0.99±0.09, HuD Rapa: 0.92±0.06). 
Surprisingly, myc-HuD favors expression in one daughter branch over the other with 
rapamycin treatment as indicated by its increased BVI (Figure 4.2 E and H; HuD DMSO: 
1.00±0.16, HuD Rapa: 2.27±0.59). This suggests that myc-HuD is more available to 
68 
protect CaMKIIα from degradation in one branch over the other resulting in CaMKIIα 
selective branch expression. 
Discussion 
Temporal and spatial regulation of protein expression is critical for a neuron to 
modify its synaptic input in an experience-dependent manner (Kandel, 2001; 
Govindariajan et al., 2006). It’s widely accepted that proteins synthesized in response to 
strong stimuli at one set of synapses are available to other nearby synapses to facilitate 
plasticity at both sets of synapses known as “synaptic tag and capture” (Frey and 
Morris, 1997). Synapses that are “bound” together and distributed on a single dendritic 
branch increase the probability that excitatory postsynaptic potential (EPSP) 
amplification will occur (Govindarianjan, et al., 2006). Molecular mechanisms that 
mediate branch-specific expression of proteins that facilitate plasticity are unknown. 
One such mechanism may be the local translation of mRNAs coding for proteins that 
are required for lasting changes in synaptic efficacy, such as CaMKIIα. We determined 
that overexpression of HuD, the RNA-binding protein that promotes the expression of 
CaMKIIα, can prevent it from being degraded when mTOR activity is reduced and 
mediates its branch specific expression. 
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Chapter 5: Conclusion 
Here, we discovered the molecular mechanism of mTOR mediated repression of 
Kv1.1. Previously, a novel mechanism of mTOR repression of local Kv1.1 translation 
was reported (Raab-Graham et al., 2006). With mTOR activity, the microRNA, miR-129-
5p, binds to and suppresses the local translation of Kv1.1. We found that in order to 
relieve repression the RNA binding protein, HuD, binds Kv1.1 mRNA and promotes its 
local translation. Surprisingly, HuD levels do not change to relieve miR-129-5p binding 
to Kv1.1. Instead, when mTOR levels are repressed, other HuD high affinity targets, 
including CaMKIIα, Homer1a, and GAP-43, mRNAs degrade releasing HuD to bind its 
low affinity targets, such as Kv1.1. 
This in vitro model allowed us to determine if these factors, miR-129-5p and 
HuD, regulate Kv1.1 expression in a disease model such as Temporal Lobe Epilepsy 
(TLE), where acute mTOR activity occurs. Previously, it has been shown that rapamycin 
treatment can prevent seizures in TLE suggesting that mTOR signaling is critical in TLE 
development (Zeng et al., 2009). We first determined the time course of mTOR 
dependent regulation of Kv1.1 following status epilepticus (SE). mTOR levels 
significantly drop 14 days post-SE corresponding to the peak of Kv1.1 levels in TLE. 
When mTOR levels were elevated at 21-30 days post-SE resulting in a significant 
increase in the number of behavioral seizures, Kv1.1 expression was significantly 
impeded by miR-129-5p. This drop in Kv1.1 led to a hyperpolarized action potential 
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threshold which could potentially contribute to the increased hyperexcitability observed 
in TLE. 
This work has raised several new interesting questions. One of those questions 
is elucidating how a drop in mTOR activity may result in specific mRNAs to degrade. 
We have begun to address this question of elucidating how certain mRNAs may be 
targeted to degrade once mTOR activity drops (Chapter 4) and how this mRNA 
degradation may mediate differential branch expression. Secondly, are these regulatory 
factors of Kv1.1, important for the development of other diseases where mTOR activity 
is affected, including Alzheimer, Parkinson’s, and Cancer (Costa-Mattioli and 
Monteggia, 2013; Hoeffer and Klann, 2010; Wong 2013). Thirdly, how are miR-129-5p 
levels elevated in TLE and finally, there are several predicated targets of miR-129-5p 
that have significant functions in the nervous system that may be regulated similarly to 
Kv1.1. 
There is a growing body of evidence illustrating the importance of proper control 
of local translation and maintaining the balance of regulatory factors that oversee local 
translation. mTOR activity also has an important role as disruption of this key signaling 
pathway underlies many neurodegenerative diseases. The importance of the proper 
regulation and expression of Kv1.1 cannot be overstated. Lack of Kv1.1 results in 
development of seizures and therapeutic intervention with Kv1.1 overexpression blocks 
seizure activity (Wykes et al., 2012). Inhibition of mTOR with rapamycin blocks seizure 
progression (Zeng et al., 2009). However, long term treatment with rapamycin may have 
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severe side effects due to mTOR being a major signaling pathway involved in several 
important neural system functions (Costa-Mattioli and Monteggia, 2013; Hoeffer and 
Klann, 2010; Wong 2013). Finding key targets downstream of mTOR, such as Kv1.1 
and possibly miR-129-5p, to effect may have less adverse side effects while still 
preventing disease. 
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Chapter 2 Figures 
Figure 2.1. mTORC1 Kinase-dependent Repression of Kv1.1 is not 
Due to mRNA Stability
(A) SN were isolated from DMSO or rapamycin treated DIV21 cortical neurons. 
Representative western blots and quantification indicate the relative level of p-
mTOR/mTOR and Kv1.1/tubulin (loading control). *** p< 0.001. *< 0.05, unpaired 
student’s t-test. Error bars = SEM. p-mTOR: n=7; Kv1.1: n=5 over 2 independent 
cultures. 
(B) SN RNA was isolated from DMSO or rapamycin treated cortical neurons and Kv1.1 
mRNA was detected via RT-qPCR. Representative DNA gel of RT-qPCR samples 
showing amplification of a specific Kv1.1 band. Error bars =SEM. DMSO: n=5; 
rapamycin: n=6 over 3 independent cultures 
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Figure 2.2. Overexpression of Kv1.1 3’ UTR removes endogenous 
repression factors leading to increased Kv1.1 protein. 
Left, representative neurons infected with Sindbis virus coding for control RNA (Kaede-
MAP2 DTS) or Kv1.1 3’ UTR (DIV21). Neurons were treated with DMSO or rapamycin. 
Scale bar = 20 µm. Right, quantification of surface expression of Kv1.1. ***p< 0.001, 
unpaired student’s t-test. Control+DMSO: n=16 neurons, 21 dendrites; 3’ UTR+ DMSO: 
n=17 neurons; 20 dendrites, control+Rapa: n=7 neurons, 8 dendrites, 3’ UTR+Rapa: 
n=10 neurons, 11 dendrites. Error bars =SEM. 
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Figure 2.3: miR-129 Binds 
Kv1.1 RNA when mTORC1 
Kinase is Active. 
(A) Sequence alignment of Kv1.1 
3’UTR indicates that the miR-129 seed 
match sequence (binding to nucleotide 
(nt) 2-8 of miR-129) is conserved 
among rat, mouse, guinea pig, and 
human, with nt 1 and 8 being less 
conserved. The miR-129 binding site  
is highlighted in red. Nucleotide 
number after the stop codon of each 
sequence shown: Rat, 181-212 nt; 
mouse, 177-207 nt; guinea pig, 1-34 
nt; human 1-35 nt. The NCBI 
accession numbers are: rat M26161.1, 
mouse NM_010595, and human 
BC101733.1. For guinea pig, the 
UCSC genome browser database was 
used. The sequence is located in scaffold_107:2955798-2955831. (B) Above, 
schematic of RNA fragments used as bait to determine miR-129 binding to Kv1.1. 
mTRS indicated by gray box illustrating the miR-129 seed match sequence (FL) or the 
mutated sequence (∆miR-129). Below, qPCR of miR-129 pulled down from DMSO or 
rapa treated neurons. *p<0.05, ***p<0.001, one-way ANOVA, Dunnett’s post-test 
compared to the FL DMSO. DMSO: FL n=11, CR n=8, ∆miR-129 n=5; rapa: FL n=6, CR 
n=8, ∆miR-129 n=4 over at least 4 independent cultures.  CR: coding region; FL: Full-
length. (C) Left, representative neurons transfected with EGFP alone (control) or with 
LNA to specifically knockdown miR-129 (KD). Arrows indicate Kv1.1 puncta in 
dendrites. Scale bar = 20 µm. Right, quantification of dendritic Kv1.1 punctal signal 
intensity. # dendrites: control: n=12; miR-129 KD: n=14. 9 neurons for each condition. 
***p<0.001, unpaired student’s t-test. (D) Left, representative neurons transfected with  
EGFP alone (control) or with LNA against miR-129 (KD). Right, quantification of 
dendritic Kv4.2 puncta. # dendrites: control: n=12; miR-129 KD: n=17. n= 8 and 10 
neurons for control and miR-129 knockdown, respectively. (E) Left, hippocampal 
neurons transduced with either DsRed-control or DsRed-pre-miR129-2 lentivirus at 
DIV14. DMSO or rapa treated DIV21 neurons were stained and imaged for RFP and 
Kv1.1. Right, quantification of signal intensity. *** < 0.001, one-way ANOVA Tukey post-
test. n=9 neurons per treatment. # dendrites: DMSO, Rapa: control n=17; n=14 and 15 
for miR-129 OE. 
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Figure 2.4: Mutating the miR-129 Seed Match Sequence in Kaede-
Kv1.1 mRNA Results in mTORC1-independent New Translation in 
Neuronal Dendrites. 
Live imaging of cultured hippocampal neurons expressing Kaede-Kv1.1 with (top panel, 
FL) or without (bottom panel, ∆miR-129) seed match sequence of miR-129 in aCSF 
containing DMSO (left, control) or rapamycin (right, 200 nM) before, immediately after (0 
time point), and 120 min after UV exposure to photoconvert Kaede-Kv1.1. Left: entire 
representative neuron. Right: blown up representative dendrite, indicated by arrows, 
greater than 60 µm from the soma. Large image: scale bar=50 µm, Insert: scale bar=10 
µm. DMSO: FL n= 58 puncta, ∆miR129 n=67 puncta; Rapamycin: FL n=51 puncta, 
∆miR-129 n=64. *p< 0.05 and **p< 0.01 one-way ANOVA, Tukey post-test, relative to 
Kaede-Kv1.1-FL DMSO. Error bars = SEM.  
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Figure 2.5. Mutating the miR-129 Seed Match Sequence in EGFP-
Kv1.1 RNAIncreases Protein Levels without Changing RNA Levels. 
Representative images of dendritic localization of EGFP-Kv1.1 RNA (red) and protein 
(green) with the intact (left, FL) or mutated (right, ΔmiR-129) miR-129 binding site 
revealed by in situ hybridization using a digoxigenin-labeled antisense oligo against 
EGFP. Scale bar = 20 μM, n=12 and 13 neurons for FL and ΔmiR-129, 40 dendrites 
each. Error bars = SEM. 
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Figure 2.6. HuD Binds Kv1.1 
mRNA when mTORC1 Kinase 
is Inhibited and Increases 
Kv1.1 Expression that is 
Reversed with Cycloheximide. 
(A) Left, RT-qPCR amplification of miR-
129 from neurons treated with DMSO 
or rapamycin. n=3 independent cultures 
and each sample was done in triplicate. 
The signal intensity for miR-129 was 
normalized to the signal intensity for let-
7a which remained constant between 
DMSO or rapamycin treated neurons. 
As a loading control, ethidium bromide-
stained low-molecular-weight RNA is 
shown in the bottom panel (labeled as 
EtBr). (B) RT-PCR amplification of 
Kv1.1 mRNA pulled down by HuD in 
HEK cells. HEK cells were co-
transfected with myc-HuD and Kaede-
Kv1.1 FL, CR, or ΔmiR-129. Anti-myc 
coated beads were used to pull down 
HuD bound to Kv1.1 mRNA outlined 
above. n=2 independent cultures. (C) 
Left, representative neurons (DIV14) 
co-transfected with EGFP and either pcDNA or HuD cDNA. Neurons were treated with 
DMSO or cycloheximide (50 µM) and Kv1.1 and Kv4.2 were detected with specific 
antibodies. Right, quantification of Kv1.1 and Kv4.2 punctal intensity in dendrites. # 
dendrites: DMSO: Kv1.1 pCDNA n=15, HuD n=18; Kv4.2 pCDNA n=17, HuD n=16. 
Cycloheximide: Kv1.1 HuD n=14, Kv4.2 HuD n=17. ***p<0.001, one-way ANOVA, 
Tukey’s post-test. # Kv4.2 punctal intensity significant from DMSO+HuD. (D) RT-PCR 
amplification of Kv1.1 (top panel), GAP-43 or CaMKIIα (middle panel) mRNA copurified 
with GST-HuD or GST from DMSO or rapamycin treated cortical neurons (DIV21). 
GAPDH mRNA was detected in input but not pulldown (bottom panel). The ratio 
(Rapa/DMSO; right of the images) is determined by subtracting signal intensity of 
background GST band from the specific GST-HuD band and normalizing each band by 
their respective GAPDH input mRNA levels. HuD-RNA pulldown was replicated with 3 
independent cultures for Kv1.1 mRNA and two independent cultures for CaMKIIα and 
GAP-43 mRNA. Significance for each mRNA was determined by a single t-test. *p<0.05 
indicating the binding is significantly different from 1. A value of 1 suggests equal 
binding in both treatments. 
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Figure 2.7. HuD Binding to 
Kv1.1 mRNA Coincides with 
Reduced Levels of other HuD 
Target mRNAs. 
(A) Western blot analysis of HuD from 
synaptoneurosomes isolated from 
neurons treated with DMSO or 
rapamycin. DMSO: n=3; Rapa: n=4 
over 2 independent cultures. (B) RT-
qPCR analysis of CaMKIIα, GAP-43, 
Homer1a, and Kv1.1 mRNA isolated 
from control or rapamycin (200 nM) 
treated neurons normalized to the 
internal housekeeping gene, GAPDH 
which remains constant between the 
two conditions. CaMKIIα and Kv1.1: 
n=3, GAP-43: n=5, Homer1a: n=4; 
three-five independent cultures. 
Control was normalized to 100% and 
is indicated by dotted line on the 
graph. The mRNA target of HuD is 
shown as % remaining following 
rapamycin treatment. One-sample t-
test was done to determine statistical 
significance from control. Error bars = 
SEM. *p<0.05. (C) Representative blot 
and quantification of SNCaMKIIα 
protein isolated from DMSO or rapa treated cortical neurons. Error bars = SEM. 
*p<0.05. DMSO: n=5; Rapa: n=6. (D) Neurons were treated with Actinomycin D (12 µM)
for 4-5 hrs prior to treating with DMSO or rapamycin for 75 min. Degradation was 
measured by RT-qPCR for CaMKIIα mRNA and reported as the percent decrease with 
the addition of rapamycin relative to actinomycin alone. Error bars = SEM. n=5 per 
treatment. ***p<0.001. 
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Figure 2.8. Overexpression of the CaMKIIα UTR with Multiple HuD 
Sites Occludes the Increase in Dendritic Kv1.1 Expression. 
(A) Representative neurons (DIV 21) transfected with cDNA coding for EGFP or dGFP 
CaMKIIα UTRs were treated with DMSO or rapamycin (200 nM), fixed and 
immunostained for EGFP and Kv1.1. Quantification of dendritic Kv1.1 signal intensity 
for control (EGFP) or CaMKIIα UTR overexpression normalized by baseline signal for 
dendritic Kv1.1 under control conditions (EGFP/DMSO). # dendrites: DMSO: control 
n=22, CaMKIIα UTR OE n=29; rapamycin: control n=33, CaMKIIα UTR 
OE n=31. *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA, Tukey’s post-test. 
(B) Representative neurons expressing dGFP CaMKIIα UTR without the putative HuD 
binding sites treated with DMSO or rapamycin (200 nM) were quantitated as outlined in 
(A) of this figure. # dendrites: CaMKIIα UTR OE, DMSO: control n= 20; CaMKIIα UTR 
OE, rapamycin n= 23; ΔHuD OE, DMSO n= 20; ΔHuD OE, rapamycin n= 24. 
***p<0.001 relative to all other conditions, one-way ANOVA, Tukey’s post-test.  
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Chapter 2 Supplemental Figures 
Figure S2.1. Post-
transcriptional 
Regulation of Kv1.1 
mRNA Mediated by 
mTORC1 Kinase 
Repressive Sequence in 
the 3’UTR of Kv1.1.  
 (A) Left, representative 
western blot of total lysate or 
synaptoneurosomal (SN) 
preparation probed for the 
nuclear marker, NeuN. 
Quantification is shown of 
NeuN/Tubulin protein. Total: 
n=4; SN: n=3 over 2 
independent culture. Right, total lysate or SN preparation stained for the nuclear 
marker, DAPI. Scale bar = 10µm. 
(B) Schematic of competition assay where DIV21 cortical neurons were infected with a 
Sindbis virus coding for the 3’ UTR of Kv1.1. Overexpression of Kv1.1 3’ UTR is 
predicted to remove the inhibitory factor(s) from endogenous Kv1.1 and therefore result 
in an increase in the endogenous surface expression of Kv1.1. (C) Representative 
neurons infected with Sindbis virus coding for control RNA (Kaede-MAP2 DTS) or Kv1.1 
3’ UTR (DIV21) show similar morphology. Scale bar = 20 µm. (D) Surface expression of 
Kv1.1 in the cell body of neurons infected with either control RNA (Kaede-MAP2 DTS) 
or Kv1.1 3’ UTR. 18 hours post-infection neurons were treated with either carrier 
(DMSO) or rapamycin. Kv1.1 intensity is normalized to Kaede expression. Related to 
Figure 2.2. Error bars represent SEM.  
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Figure S2.2. miR-129 Binds 
to Kv1.1 mRNA when 
mTOR is On and Reduces 
Kv1.1 Expression. 
(A) Schematic of RNA affinity 
capture assay used to identify 
factors binding to Kv1.1 mRNA. 
Kv1.1 FL, Kv1.1 CR, or Kv1.1 (B) 
Representative melt curves of real-
time PCR for miR-129 pulled down 
by Kv1.1 RNA (related to Figure 
2.3B; n=3 independent cultures). FL, 
full length Kv1.1 RNA with mTRS; 
CR, coding region of Kv1.1 RNA; 
ΔmiR-129 , full length Kv1.1 RNA 
with miR-129 seed match sequence 
mutated; RFU, relative fluorescent 
unit.  (C) miR-129 pull-down from SN 
as determined by qPCR and 
normalized to 10% total RNA input. 
(n=3 rats done in duplicate) Control, no RNA. * indicates p<0.05, ** indicates p<0.01. 
Error bars indicate SEM. (D) miR-129 levels were reduced in cortical neurons 
transfected with LNA against miR-129 compared to scrambled LNA, as shown by 
northern blot analysis. miR-129 levels were normalized to the miRNA, let7; The data 
shown are from a single representative experiment out of two repeats; For the 
experiment shown n=2. Error bar = SEM. As a positive control for LNA inhibition of miR-
129, SNs isolated from transfected cortical neurons were immunoblotted using an ERK2 
specific antibody. SC and LNA: n=3 over 2 independent cultures. (E) Top: 
Representative neurons EGFP+Scrambled (SC) or EGFP+miR-129 Knockdown (KD) 
LNA for Kv1.1 and Kv4.2. Bottom left, quantification of Kv1.1 showed ~2 fold increase in 
punctal signal intensity with no change in Kv4.2 (middle). *** indicates p<0.001. Kv1.1, 
SC: n=9 and 12, LNA: n=7 and 12, neurons and dendrites, respectively. Kv4.2, SC: n=9 
and 14, LNA: n=5 and 8 neurons and dendrites, respectively. Bottom, right: cell body 
analysis of neurons co-transfected with EGFP+SC or EGFP+miR-129 KD LNA. Kv1.1 
intensity is normalized to EGFP signal. Error bars indicate SEM. (F) Kv1.1 intensity 
measured in the cell body of hippocampal neurons transduced with either DsRed-
control or DsRed-pre-miR-129-2 lentivirus at DIV14. At DIV21 neurons were treated 
with either DMSO or rapamycin. Kv1.1 intensity is normalized to Red fluorescent protein 
signal. Related to Figure 2.3E. Error bars represent SEM.  
82 
Figure S2.3. Mutation of miR-129 Binding Site in mTRS Increases 
Kv1.1 Protein Level without Changing the RNA Level. 
As described in figure 2.4, neurons were infected with sindbis virus coding for EGFP-
Kv1.1 RNA with the intact (FL) or mutated (∆miR-129) miR-129 binding site. Kv1.1 
protein level was then determined by immunofluorescence and the RNA level 
determined by in situ hybridization (ISH) using a digoxigenin-labeled antisense oligo 
against EGFP. (A) Quantification of ISH signal (representing the RNA level). (B) 
Quantification of EGFP signal to control for volume (representing the Kv1.1 protein 
level).  The result reveals that the exogenous RNA levels are relatively equal between 
constructs with a significant increase in protein level with ∆miR-129. FL: n=12 neurons; 
∆miR-129: 13 neurons; n=40 dendrites each. Error Bars represent SEM. 
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Figure S2.4.  Predicted 
Low-Affinity HuD Binding 
Sites in the CR of Kv1.1 
mRNA and HuD Binding 
to EGFP-CaMKIIα UTR, 
with Predicted HuD 
Binding sites, results in 
Increased EGFP levels.  
(A) Top, cartoon of Kv1.1 coding 
region (CR) and mTRS indicating 
the approximate sites of the 
predicted HuD and verified miR-
129 binding sites. Below, the CR of 
Kv1.1 has 3 motifs that are 
consistent with the 8-nucleotide 
consensus sequence identified by 
Wang and Tanaka-Hall, and are 
equivalent to recently identified 
HuD binding motif #1(1,2). The 
alignment of these potential HuD 
binding sites with the consensus sequences are shown below with red residues 
representing U, blue residues representing C or U, and black residues representing 
arbitrary nucleotides. (B) Kv1.1 intensity measured in the cell body of neurons co-
transfected with EGFP and either pcDNA or HuD cDNA. Neurons were treated with 
DMSO or cycloheximide (50 µM). Kv1.1 intensity is normalized to EGFP. Related to 
Figure 2.6C. Error bars represent SEM. * < 0.05. (C) Sequence of CaMKIIα cDNA 
coding for the 3’ UTR included in the construct used for the competition assay in Figure 
2.7A and B. Underlined sequence indicates region of 8 putative HuD binding sites as 
denoted below by nucleotide number (HuD motif 1). Highlighted in yellow is the region 
removed to eliminate the HuD binding sites as a control for Figure 2.7B. 
(D) HEK293T cells were transfected with EGFP-CaMKIIα UTRs plus either pCDNA or 
HuD and total protein was isolated. Representative blot of EGFP and Tubulin are shown 
with quantification below. HuD overexpression resulted in a significant increase in 
EGFP protein as a possible result of binding CaMKIIα UTRs. There are 8 predicted 
overlapping HuD binding sites within this 3’UTR of CaMKIIα. Error bars represent SEM. 
* indicates p<0.05. n=4 for control and HuD.
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Figure S2.5. Model for Bidirectional Regulation of Kv1.1 mRNA 
Translation. 
With NMDAR/mTORC1 activation, miR-129 binds Kv1.1 mRNA while HuD binds to its 
high-affinity targets, such as CaMKIIα mRNA, repressing Kv1.1 mRNA translation (left 
dendrite). With mTORC1 inhibition, HuD’s high affinity targets are degraded, increasing 
the available HuD to bind to its low affinity targets. As a result, HuD binds to Kv1.1 
mRNA and miR-129 binding is relieved, promoting Kv1.1 mRNA translation resulting in 
more Kv1.1 channels on the dendritic membrane (right dendrite). mTORC1 regulated 
CaMKIIα mRNA degradation serves as a switch to release HuD and allow its binding to 
Kv1.1 mRNA mediating the local translation of Kv1.1 mRNA. 
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Chapter 3 Figures 
Figure 3.1: Number of Behavioral Seizures increase at 21 days post-
SE. 
Day 2 after KA injected rats reached SE, they were placed in an isolated room where 
they were continuously video monitored for the progression of behavioral seizures until 
day 21 post-SE. KA rats were scored by number of behavioral seizures ranging from 
Class III-V. *<0.05; **<0.01. P value represents significance to 21 days post-SE by One-
way ANOVA Newman-Keuls post test. 
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 Figure 3.2: Differential mTOR 
activity occurs post-SE. 
(A) Hippocampal SN protein was isolated from 
0d (control, saline+PB) and kainic acid (KA+PB) 
treated animals 2, 5, 14, 15 and 21-30 days post-
SE.  Top, representative Western blot of a SDS-
PAGE gradient gel probed with antibodies 
against p-mTOR and mTOR. Quantification of p-
mTOR signal normalized by mTOR levels and 
relative to 0d is shown below. control: n=20, 2d 
post-SE: n=6, 5d post-SE: n=5,  14d post-SE: 2, 
15d post-SE: 3, 21-30d post-SE: n=9. *<0.05, 
***<0.005. One-way ANOVA Dunnett post test.   
(B) Hippocampal SN protein was isolated from 
control (saline+PB) and kainic acid (no SE) 
treated animals that did not progress past class 
III. ~90% of animals injected with KA reach
Class V. Representative Western blot of a SDS-
PAGE gradient gel probed with antibodies 
against p-mTOR and mTOR with the  
quantification of p-mTOR signal normalized by 
mTOR levels is shown. Control: n=4, no SE: n= 
5. Error bars are SEM.
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 Figure 3.3: Reduced mTOR activity 
results in peak Kv1.1 protein levels at 
14d post-SE whereas when mTOR 
activity is increased 21-30 days post-SE 
Kv1.1 levels drop. 
(A) Hippocampal SN protein was isolated from 0d 
(control, saline+PB) and kainic acid (KA+PB) 
treated animals 2, 5, 14, 15 and 21-30 days post 
SE.  Top, representative Western blot of a SDS-
PAGE gradient gel probed with antibodies against 
Kv1.1 and tubulin. Quantification of Kv1.1 signal 
normalized by tubulin levels and relative to 0d is 
shown below. *p<0.05. ***p<0.005. One-way 
ANOVA Tukey post test. Control: n=18, 2d post-
SE: n=6, 5d post-SE: n=5, 14d post-SE: n=2, 15d 
post-SE: n=3, 21-30d post-SE: n=5. Error bars 
represent SEM.   
(B) Representative Western blot of a SDS-PAGE 
gradient gel probed with antibodies against Kv1.1 
and tubulin and  quantification of Kv1.1 signal 
normalized by tubulin levels is shown. Control: 
n=4, no SE: n= 5. Error bars represent SEM.   
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Figure 3.4: Kv1.1 protein increases 14 days post-SE and decreases 
30 days post-SE in the CA1 and CA3 region. 
(A) Coronal slices from control and 14 days post-SE rats were immunostained for Kv1.1 
and tubulin (volume control) followed by imaging with the Leica microscope 20x 
objective. Representative slices are shown of the CA1 and CA3 region from 14 days 
post-SE rats. Kv1.1 is pseudocolored green and tubulin is pseudocolored red. 
(B) Coronal slices from control and 21-30 days post-SE rats were immunostained for 
Kv1.1 and tubulin (volume control) followed by imaging with the Leica microscope 20x 
objective. Representative slices are shown of the CA1 and CA3 region from 30 days 
post-SE rat. Kv1.1 is pseudocolored green and tubulin is pseudocolored red. 
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Figure 3.5: CA1 pyramidal neurons 
have a more hyperpolarized action 
potential threshold and reduced 4-AP 
sensitivity post SE. 
(A) Voltage recordings showing a single action 
potential elicited by a 100-msec current injection 
before (thin line) and after (thick line) application of 
50 µM 4-AP from control (black) and 21-30d post-
SE (red) CA1 neurons. (B) The threshold of action 
potentials elicited by 100-msec current injection is 
significantly hyperpolarized at 21-30d post-SE 
relative to control. 4-AP application significantly 
hyperpolarized the threshold of action potentials in 
control but not 21-30d post-SE neurons. **p<0.01, 
****p<0.001. (C) There is no significant difference 
in action potential threshold elicited during the 2-
msec steps between control and 21-30d post-SE 
CA1 neurons. 4-AP has no significant effect on 
action potential threshold in either control or 21-
30d post-SE neurons. (D) Summary data showing 
that 4-AP significantly hyperpolarized action 
potential threshold in control but not 21-30d post-
SE neurons for the 100-msec current injection. 
****p<0.001 compared to 21-30d post-SE. 
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 Figure 3.6: The negative regulator of 
Kv1.1 expression (miR-129-5p) is 
elevated 21-30d post-SE correlating 
with decreased Kv1.1 and a 
hyperpolarized action potential 
(A) Hippocampal SN RNA isolated from 0d 
(saline+PB) and kainic acid (KA+PB) treated 
animals 21-30 days post SE.  RT-qPCR analysis of 
miR-129-5p levels normalized to 5S rRNA is shown. 
Note, increased miR-129-5p levels are shown 21-30 
days post-SE. 0d: n=9, 21-30d: 10. *<0.05 Error 
bars = SEM.  
(B) Hippocampal SN protein isolated from 0d 
(saline+PB) and kainic acid (KA+PB) treated 
animals 21-30 days post SE. Representative blot of 
HuD and tubulin is shown. Quantification of HuD 
normalized to tubulin is shown below. 0d no-SE: 
n=7, 21-30d post-SE: n=7  Error bars represent 
SEM.  
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Figure 3.7: Model for post-transcriptional regulation of 
bidirectional changes in Kv1.1 expression in TLE. 
Left panel, under conditions where mTOR activity is off Kv1.1 mRNA repression via 
miR-129-5p is relieved by HuD resulting in Kv1.1 expression. In contrast, when mTOR 
activity is on miR-129-5p binds to Kv1.1 mRNA and HuD is released. Under normal 
conditions the relative levels of miR-129-5p and HuD do not change to favor Kv1.1 
binding (Sosanya et al., 2013). At later stages of TLE (21-30 days post-SE), when 
mTOR activity is elevated, miR-129-5p levels increase favoring translational repression 
of Kv1.1 mRNA (red arrow) leading to neuronal hyperexcitability. 
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Chapter 4 Figures 
Figure 4.1. mTOR 
blockade removes 
CaMKIIα branch 
variability by 
promoting the rapid 
degradation of 
CaMKIIα. (A) Cultured
hippocampal neurons 
transfected with 
pCDNA+eGFP were treated 
with DMSO or Rapamycin 
and immunostained for 
CaMKIIα. Representative 
neurons are shown. White 
boxes indicate the primary 
and secondary branches 
where signal intensity 
measurements were taken 
in B, C, and D. (B) The 
signal intensity of CaMKIIα 
in neurons treated with 
DMSO or Rapamycin was 
measured as a ratio over 
eGFP, 10 µm before the 
branch point. As a control, Kv1.1 signal intensity was also measured. *<0.05, ***<0.005. 
(C) The signal intensity of CaMKIIα in neurons treated with DMSO or Rapamycin was 
measured as a ratio over eGFP, 10 µm after the branch point. Note, CaMKIIα protein 
decreases with rapamycin treatment. As a control, Kv1.1 signal intensity was also 
measured. *<0.05. (D) The difference between CaMKIIα protein was measured between 
daughter branches and graphed as branch variability index or BVI. **<0.01. (E) Neurons 
treated with rapamycin for 0, 60, 90, and 180 min were harvested from cultured neurons 
and PCR was performed with specific primers. Above, schematic of CaMKIIα internal 
primers (a and b) and primers that recognize the poly(A) tail of CaMKIIα. (F) As a 
control, PCR was performed following RNase H treatment. (G) As a control, PCR was 
performed using Kv1.1 specific primers and primers that recognize the poly(A) tail of 
Kv1.1. Note, neither the poly(A) tail or the mRNA levels of Kv1.1 change in rapamycin 
treated neurons. 
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Figure 4.2. myc-
HuD differential 
branch 
expression 
rescues reduced 
CaMKIIα 
Branch 
Variability. 
 (A) Cultured 
hippocampal neurons 
were transfected with 
pCDNA+eGFP or 
HuD+eGFP, and 
treated with either 
carrier (DMSO) or 
rapamycin. 
Representative 
neurons stained for 
CaMKIIα are shown. 
CaMKIIα protein is 
indicated as a heat 
map. (B) Primary (10 
µm before branch 
point) dendritic 
CaMKIIα protein was 
measured as a ratio 
over eGFP. *<0.05 
significantly different 
from pCDNA DMSO 
neurons. (C) CaMKIIα protein in daughter branches (10 µm after the branch point) was 
measured as a ratio over eGFP. *<0.05 significantly different from pCDNA Rapa 
neurons. (D) The difference between CaMKIIα/eGFP protein was measured between 
daughter branches and graphed as BVI. *<0.05 significantly different from pCDNA Rapa 
neurons. (E) Cultured hippocampal neurons were transfected with pCDNA+eGFP or 
HuD+eGFP, and treated with either carrier (DMSO) or rapamycin. Representative 
neurons stained for myc-HuD are shown. myc-HuD protein is indicated as a heat map.  
(F) Primary (10 µm before branch point) dendritic myc-HuD protein was measured as a 
ratio over eGFP. (G) myc-HuD protein in daughter branches (10 µm after the branch 
point) was measured as a ratio over eGFP. (H) The difference between myc-HuD/eGFP 
protein was measured between daughter branches and graphed as BVI. *<0.05. 
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